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Abstract 
Regulatory and killer function in B-cells have been described during tuberculosis (TB) disease, and 
these were shown to regulate inflammation through several mechanisms including both cytokine 
secretion (IL-10, IL-35, TGF-β, sFas-L and Granzyme-B) and cell surface expression of Fas-L, PD-
L1 and FoxP3.  
During TB treatment, binding immunoglobulin protein (BiP) secretion was assessed through Enzyme 
Linked ImmunoSorbent (ELISA) assay. This included plasma samples from healthy controls (n=32), 
TB diagnosis (n=29), week-1 follow up (n=8), month-2 follow up (n=7), and month-6 follow up 
(n=19) with additional collection from 20 participants (month-6 total (n=39)). Increased detection of 
BiP in plasma was observed between TB diagnosis and week-1 follow up suggesting a metabolism 
shift due to cell stress. 
The effect of extracellular BiP on immune cell responses were determined by stimulating Peripheral 
Blood Mononuclear Cells (PBMCs) isolated from healthy controls (n=12) and Mycobacterium 
tuberculosis (M.tb) exposed participants (LTBI) (n=8) with human recombinant BiP at 20 µg/ml. 
This effect was compared to other antigenic material including Toll-like Receptor-9 agonist (TLR-
9a), M.tb H37Rv, Isoniazid (INH), BiP+TLR-9a, pooled Bronchoalveolar Lavage (BAL) fluid at TB 
diagnosis (TBdx) and month 6 TB treatment (M6) with unstimulated PBMCs as a baseline control. 
From this, the cytokine profile was established which indicated an elevated level of sFas-L and IL-
13 by BiP stimulation. Further, increased frequency of CD19+CD5+ B-cells co-expressing Fas-L and 
IL-5Rα was greatly induced by BiP in both healthy controls and LTBI participants. Kinase activity 
was assessed by Luminex multiplex assay between unexposed group, M.tb exposed and stimulation 
conditions. Taken together, this study shows BiP potential to aid in better M.tb control by 
upregulating a B-cell population with immune regulatory function through expression of Fas-L. This 
highlights the potential use of BiP in host directed therapies (HDT) during TB disease to aid in better 
infection response. 
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Opsomming 
Regulerings- en vernietigingsaksie in B-selle is tydens tuberkulose (TB) siekte beskryf, en daar is 
getoon dat ditinflammasie deur verskeie meganismes reguleer, insluitende sitokiensekresie (IL-10, 
IL-35, TGF-β, sFas-L en Granzyme -B) en seloppervlakte uitdrukking van Fas-L, PD-L1 en FoxP3. 
Tydens TB behandeling, is bindende immunoglobulien proteïen (BiP) sekresie geassesseer deur ‘n  
Enszyme Linked ImmunoSorbent Assay (ELISA) toets. Plasma monsters van gesonde pasiënte (n = 
32), TB pasiënte tydens diagnose (n = 29), week 1 opvolg (n = 8), maand 2 opvolg (n = 7) en maand-
6 opvolg n = 19) met die bykomende versameling van 20 deelnemers (maand-6 totaal (n = 39)) is 
ingesluit. Verhoogde BiP vlakke in plasma is waargeneem tussen TB diagnose en week 1 opvolg wat 
'n metabolisme verskuiwing weens selspanning aandui. 
Die effek van ekstrasellulêre BiP op immuun sel response is bepaal deur die stimulering van perifere 
bloed mononukleêre selle (PBMCs) wat geïsoleer is van gesonde kontroles (n = 12) en 
Mycobacterium tuberculosis (M.tb) blootgestelde deelnemers (LTBI) (n = 8) met menslike 
rekombinante BiP van 20 μg/ml. Hierdie effek is in vergelyking met ander antigeenmateriaal, 
insluitend Toll-like Receptor-9-agonist (TLR-9a), M.tb H37Rv, Isoniazid (INH), BiP + TLR-9a, 
saamgevoegde Bronchoalveolêre spoeling (BAL) vloeistof by TB diagnose (TBdx ) en maand 6 TB 
behandeling (M6) met ongestimuleerde PBMCs as 'n basislynbeheer. Hieruit is die sitokienprofiel 
vasgestel wat 'n verhoogde vlak van sFas-L en IL-13 deur BiP-stimulasie aangedui het. Verder is 
gevind dat verhoogde frekwensie van CD19+CD5+ B-selle wat Fas-L en IL-5Rα terselfdetyd 
uitdrukveroorsaak word deur BiP in beide gesonde pasiënteen LTBI-deelnemers. Kinase-aktiwiteit is 
geassesseer deur Luminex-multipleks assessering tussen die nie-blootgestelde groep, M.tb blootgestel 
en stimulasie toestande. Hierdie studie het dus getoon dat BiP potensiaal het om M.tb beheer te 
verbeter deur 'n B-sel bevolking met immuunregulerende funksie te reguleer deur die uitdrukking van 
Fas-L. Hierdie resultatedui op diedie potensiële gebruik van BiP in gasheergerigte terapieë (HDT) 
tydens TB-siekte om beter infeksierespons te bevorder. 
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
Acknowledgements 
I would like to thank the following individuals for their endless support towards completion of my 
M. Sc. degree. 
Firstly, I would like to thank my supervisor, Dr. André G. Loxton, for affording me this prestigious 
opportunity to be part of a growing research community. Thank you for the continuous support, 
guidance and knowledge provided to aid in completion of this study. 
Special thanks to my family for their endless support during this process and for allowing me to take 
this chance and enrol for higher studies. 
I would like to extend my sincere gratitude to all my study participants; completion of this study 
would have been impossible without your love and support. 
Extended gratitude to the SU-IRG family under leadership of Prof G. Walzl for the love and support 
during this process. 
My sincere thanks to the Molecular Biology clinical team, particularly Dr. Stephanus Malherbe, Dr. 
Andriette Hiemstra and Dr. Petri Ahlers for taking time and assistingt me with sample collection. 
Thank you to all my lab colleagues and office mates particularly, Dannielle Moore, Vinzeigh Leukes, 
Devon Allies, Dr. C. Beltran, Andrea Gutschmidt, Candice Snyders, Ilana van Rensburg and Dr. Zhou 
Fang for the support, knowledge, training and troubleshooting offered when science couldn’t make 
sense. Sincere thank you to Dr Liezel Smith and Dr Elizma Streicher for assistance with Afrikaans 
translations. 
Special thanks to Belinda Kriel, Dr. Novel Chegou and Dr. Nasiema Allie for the extended knowledge 
shared during training sessions.  
A big thank you to National Research Foundation (NRF) for financial support during my studies; 
without this, enrolling for my M. Sc degree would have not been possible. 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
v 
 
List of abbreviations 
 
ATF6  Activating Transcription Factor 6 
APC  Antigen Presenting Cell 
BiP  Binding Immunoglobulin Protein  
BCG  Bacillus Calmette-Guerin 
BCR  B-cell Receptor 
B-reg  Regulatory B-cell 
CD  Cluster of Differentiation 
CHOP  C/EBP homologous protein  
CIA  Collagen Induced Arthritis 
CTRL  Control group 
ER  Endoplasmic Reticulum 
EAE  Experimental Autoimmune Encephalomyelitis 
GRP78 Glucose Regulated Protein 78  
H37rv  Mycobacterium tuberculosis strain 
HDT  Host Directed Therapy 
HLA-DR Human Leukocyte Antigen DR  
IL  Interleukin  
INH  Isoniazid 
IRE-1  Inositol Requiring Enzyme 1 
Stellenbosch University  https://scholar.sun.ac.za
vi 
 
LTBI  Latent tuberculosis infection 
M2  Month-2 anti-TB treatment 
M6  Month-6 anti-TB treatment 
MFI  Mean Florescent Intensity 
MHC  Major Histocompatibility Complex 
M.tb  Mycobacterium tuberculosis 
OD  Optical Density 
pAPC  professional Antigen Presenting Cell 
PBMC  Peripheral Blood Mononuclear Cell 
PD-L  Programmed Death Ligand 
PERK  Protein Kinase-like ER kinase 
p-value Probability value 
QFN  Quantiferon 
RA  Rheumatoid Arthritis 
TB  Tuberculosis 
TBdx  Tuberculosis disease diagnosis 
TGF-β  Transforming Growth factor beta 
TLR  Toll-Like Receptor 
TNF  Tumour Necrosis Factor 
UPR  Unfolded Protein Response 
Stellenbosch University  https://scholar.sun.ac.za
vii 
 
W1  Week-1 anti-TB treatment 
WHO  World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
viii 
 
List of Figures 
 
Figure 2.1: Different B-cell functional response to inflammation. Stimulation of any of the B-cell 
function depend on the nature of pathogenic material, whereas memory B-cells are long lasting 
immunological memory cells which bears specific receptors from previous infection………….…20 
Figure 2.2: Biological pathways involved in development of regulatory B-cells by various 
extracellular antigens have not yet been characterised and needs further investigations……….….21 
Figure 2.3: Circulating CD19+ B-cells have the potential to develop to regulatory B-cells with 
different regulatory markers depending on their stage of development. Regulatory trait has been 
identified within B1 cells, Marginal Zone B-cells and Transitional-2 Marginal zone B-cells…….24 
Figure 2.4: Unfolded Protein Response mediated by BiP. Activation of the ER membrane transducers 
leads to a cascade of kinases phosphorylation that either favour apoptosis through upregulation of 
CHOP and JNK activation. Similarly, cell survival can be favoured by blocking translation and 
degrading synthesized mRNA…………………………………….……………..………………….26 
Figure 3.1: Plasma sample collection at specific time point……………………………………….57 
Figure 3.2: Detection of secreted Binding Immunoglobulin Protein (BiP) during TB treatment and 
healthy states ………………………………………….……………………………………………57 
Figure 3.3: Increased levels of BiP following one week of TB treatment. Sample pairs analysed for 
changes in BiP secretion one week after the start of TB treatment ………………………………...58 
Figure 3.4: Paired time point visits during TB treatment revealed increased secretion of BiP by TB 
treatment groups…………………………………………………………………………………….58 
Figure 4.1: Gating strategy for determining killer phenotype in B-cells isolated from human 
PBMC……………………………………………………………………………………………….67 
Stellenbosch University  https://scholar.sun.ac.za
ix 
 
Figure 4.2: Gating strategy followed for activated T-cells expressing FasL, PD1 and 
IL5Rα……………………………………………………………………………………………….68 
Figure 4.3: Cell frequency percentage of Fas-L, IL-5Ra and PD-1 expression within CD5+ B-
cells……………………………………………………………………………………………...70-71 
Figure 4.4: Analysis of cell surface expression of Fas-L (CD178), IL-5Ra (CD125) and PD-1 
(CD279) on CD3+CD5(lo) T-cells……………………………………………...…………………73-74 
Figure 4.5: T-cell frequency expressing Fas-L (CD178), IL-5Ra (CD125) and PD-1 (CD279) within 
CD3+CD5(hi) population………………………………...……………………………………….76-77 
Figure 4.6: Heat map depicting relative secretion of cytokines from PBMCs stimulated with varying 
antigens under controlled environment…………………………………………..………………….79 
Figure 4.7: Cytokine secretion profile between QFN negative and QFN positive 
participants………………………………………………………………………………………80-81 
Figure 4.8: Cytokine secretion profile during PBMC stimulation in vitro with different 
antigens………………………………………………………………………………………….83-86 
Figure 4.9: Detection of phosphorylated kinases mediating Akt/mTOR pathway in PBMC isolated 
from QFN negative and QFN positive participants………………………………………………….88 
Figure 4.10: Kinase activity vary with stimulation type and Quantiferon status………………..89-92 
          
 
 
 
 
 
    
Stellenbosch University  https://scholar.sun.ac.za
x 
 
List of Tables 
Table 2.1: Defined regulatory B-cell population frequencies in healthy human individuals expressing 
different surface markers and exhibiting diverse regulatory mechanisms…………………………...31 
Table 3.1: TB treatment follow-up participants; TBdx = TB diagnosis, W1= week 1 of TB treatment, 
M2 = month 2 of TB treatment, M6 = month 6 of TB treatment, N= number of participants, LB = 
lower bound and UP = upper bound…………………………………………………………...…….59 
Table 4.1: Participant clinical and demographic information………………………….……………65 
Table 4.2: Multiple t-test analysis for statistical differences in kinase activity between QFN negative 
and positive………………………………………………………………………………………….87 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
xi 
 
Table of Contents 
Declaration ........................................................................................................................................... i 
Abstract ............................................................................................................................................... ii 
Opsomming ........................................................................................................................................ iii 
Acknowledgements............................................................................................................................ iv 
List of abbreviations .......................................................................................................................... v 
List of Figures .................................................................................................................................. viii 
List of Tables ...................................................................................................................................... x 
Chapter 1 ............................................................................................................................................ 1 
Introduction .................................................................................................................................... 1 
Background ................................................................................................................................... 1 
Research gap and study rationale ................................................................................................. 5 
Hypothesis .................................................................................................................................... 6 
Aim ............................................................................................................................................... 6 
Objectives ..................................................................................................................................... 6 
Study groups description .............................................................................................................. 7 
Chapter 2 .......................................................................................................................................... 15 
Effect of Binding Immunoglobulin Protein (BiP) on inducing regulatory B-cells during 
inflammation and disease ............................................................................................................ 15 
Summary ..................................................................................................................................... 17 
Immunity, B-cells and regulatory B-cell responses during inflammation (autoimmune/ 
infection) ..................................................................................................................................... 18 
Phenotypic identified subsets of regulatory B-cells during inflammation. ................................ 22 
Stellenbosch University  https://scholar.sun.ac.za
xii 
 
Binding Immunoglobulin Protein (BiP) affects immune cell function ...................................... 24 
Binding of extracellular BiP with immune cells ......................................................................... 28 
Regulatory function of mature/active regulatory B-cells ........................................................... 29 
Immune responses driven by low or high frequencies of regulatory B-cells ............................. 30 
Conclusion and Future perspectives ........................................................................................... 32 
Acknowledgement ...................................................................................................................... 33 
References ................................................................................................................................... 34 
Chapter 3 .......................................................................................................................................... 43 
The level of the endoplasmic reticulum stress chaperone protein - Binding Immunoglobulin 
Protein (BiP) decreases following successful TB treatment. .................................................... 43 
Abstract .......................................................................................................................................... 45 
Introduction .................................................................................................................................... 45 
Method and Materials ..................................................................................................................... 47 
Ethics statement .......................................................................................................................... 47 
Sample description ...................................................................................................................... 48 
Enzyme Linked ImmunoSorbent Assay (ELISA) analysis ........................................................ 48 
Statistical Analysis ...................................................................................................................... 49 
Results ............................................................................................................................................ 49 
BiP levels remain unchanged at diagnosis of active TB compared to healthy controls ............. 49 
TB treatment on follow up participants between TBdx and W1 ................................................ 49 
BiP levels remain unchanged from week 1 of TB treatment till the end of therapy .................. 50 
Discussion ...................................................................................................................................... 50 
Stellenbosch University  https://scholar.sun.ac.za
xiii 
 
Acknowledgement .......................................................................................................................... 52 
References ...................................................................................................................................... 53 
Chapter 4 .......................................................................................................................................... 60 
Binding immunoglobulin protein induces anti-inflammatory responses and a killer 
phenotype in B-cells during TB disease. ..................................................................................... 60 
Abstract .......................................................................................................................................... 62 
Introduction .................................................................................................................................... 63 
Material and Methods ..................................................................................................................... 65 
Ethics statement .......................................................................................................................... 65 
Participant description ................................................................................................................ 65 
Peripheral blood mononuclear (PBMC) isolation and processing ............................................. 65 
PBMC overnight stimulation ...................................................................................................... 66 
Multi-cytokine and kinase analysis ............................................................................................ 66 
Flow cytometric analysis of B- and T-cell lymphocytes ............................................................ 67 
Data analysis ............................................................................................................................... 68 
Results ............................................................................................................................................ 69 
Expression of killer phenotype in CD19+CD5+ B-cell population ........................................... 69 
Cell surface expression within CD3+CD5+ T-cells. .................................................................. 72 
Cytokine profile in unstimulated and stimulated PBMCs .......................................................... 78 
Akt/ mTOR pathway regulation during cell stimulation with different antigens ....................... 86 
Discussion ...................................................................................................................................... 93 
Acknowledgement .......................................................................................................................... 97 
Stellenbosch University  https://scholar.sun.ac.za
xiv 
 
References ...................................................................................................................................... 98 
Chapter 5 ........................................................................................................................................ 105 
Summary and Concluding Remarks ............................................................................................. 105 
Study Limitations ......................................................................................................................... 106 
Future perspectives ....................................................................................................................... 107 
Conclusion .................................................................................................................................... 107 
Appendix ......................................................................................................................................... 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
1 
 
Chapter 1 
 
Introduction 
Background 
 
Mycobacterium tuberculosis (M.tb), a causative agent of tuberculosis (TB) disease which has been 
reported by The World Health Organisation (WHO) to be responsible for 1.3 million deaths within 
HIV negative population in 2017 while leaving 10 million people latently infected (WHO, 2018). 
This pathogen can easily be transmitted from one individual to the next through aerosol particles 
where it primarily infect the lungs (Fennelly et al., 2004; Smith, 2003). It can migrate to other body 
organs such as eyes, spine, lymph nodes and meninges (Jawahar et al., 2005; Panicker et al., 2016). 
During infection, M.tb uses aerosol particles as a vector to enter through airways into the lung alveolar 
space where it is taken up by phagocytic cells such as macrophages (Delogu et al., 2013; Woo et al., 
2018). This bacterium is classified as an intracellular pathogen and has evolved mechanisms to escape 
its host immune system by supressing major histocompatibility complex (MHC) presentation of 
infected cells and also prevents membrane repair in infected cells (Divangahi et al., 2009; Noss et al., 
2000). It is also suggested that virulent M.tb  avoids the formation of phago-lysosome by preventing 
fusion between phagosome vesicles and lysosome thus allowing it to persist longer (Flynn and Chan, 
2003; Russell, 2001). Infected phagocytes secretes proinflammatory cytokines and chemokines that 
further recruit other immune cells resulting in the formation of an organized structure called 
granuloma (Domingo-Gonzalez et al., 2016). In this state, M.tb can survive for years within its host 
without causing any noticeable clinical characteristics. This phase is referred to as latent or quiescent 
stage and is characterized by proper containment of the pathogen (Flynn and Chan, 2003, 2001). 
However, within these structures, there arecontinuous interactions between uninfected immune cells 
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and infected cells (Silva et al., 2018). Alterations in this effective communication lead to necrotic 
death of infected cells thus releasing the bacteria to infect more surrounding cells (Michelet et al., 
2018). Continuous necrotic cell death of infected cells eventually leads to granuloma dissemination 
resulting in active TB disease. 
 
Secreted cytokines facilitate activation and recruitment of other immune cells to the site of infection 
(Davis and Ramakrishnan, 2009). Their secretion varies with the type of inflammation and antigenic 
material. Similarly, in vitro stimulation of isolated cells with different antigens result in differential 
cytokine profiles both within the pro- and anti-inflammatory responses (du Plessis et al., 2016a). 
Among the major pro-inflammatory cytokines secreted during M.tb infection is interferon gamma 
(IFN-γ), TNF-α and IL-1β which serves to activate macrophages and induce MHC II expression on 
lymphocytes. However, it has become evident that secretion of anti-inflammatory cytokines (such as 
IL-10, IL-35 and TGF-β) are also upregulated during inflammation (Ray et al., 2012; Shen et al., 
2014). Dysregulation in immune response may lead to either elevated levels of pro-inflammatory 
cytokines and aggressive immune responses or extremely suppressed immune responses by anti-
inflammatory cytokines. In the context of TB disease, research platforms focused on effector or pro-
inflammatory functions; thus, suggesting the need to further explore regulatory functions mediated 
by immune cells during this disease. Successful clearance of M.tb pathogen from the host requires a 
precise balance between pro- and anti-inflammatory responses, this is thought to be possible through 
host directed therapies (HDT). Induction of autophagy and apoptosis has been observed as one of the 
promising interventions in HDT during M.tb infection (Rashid et al., 2015).  
 
This infection is characterized by a delayed adaptive immune response which further allows the 
survival of the pathogen at the site of infection (Cooper, 2009; Wolf et al., 2008). During this time, 
immune responses are mediated by innate cells. Interestingly, B-cells have been shown to mediate 
both arms of immune responses; with antigen presentation during innate function and antibody and 
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cytokine secretion during adaptive responses (du Plessis et al., 2016b) which are mainly mediated by 
T-cells of both CD4+ T-helper and CD8+ cytotoxic T-cell subsets (Tan et al., 1997; Wolf et al., 1996). 
During M.tb infection, these T-cell subsets are activated through recognition of short and long M.tb 
peptides which are displayed on MHC I and II by APCs. Regulatory cells regulate effector cell 
functions; these arise from B- and T-lymphocytes; and has been implicated to participate in M.tb 
control through secretion of anti-inflammatory cytokines and induction of apoptosis in infected cells 
(Hirsch et al., 2016; Iwata et al., 2011; Oddo et al., 1998). A subpopulation of B-cells with regulatory 
function expressing death ligands (Fas-L and PD-L1) has been defined during both inflammation and 
healthy state (Khan et al., 2015; van Rensburg et al., 2017; van Rensburg and Loxton, 2018; Wang et 
al., 2017). However, factors inducing this phenotype in B-cells remain unknown and so does their 
role during chronic TB disease. Availability of binding immunoglobulin protein (BiP) in extracellular 
fluids has been linked with the induction of immune regulatory functions during rheumatoid arthritis 
and other autoimmune diseases (Bläss et al., 2001; Shields et al., 2015; Yoshida et al., 2011). 
However, this has never been evaluated during chronic inflammatory conditions such as TB disease. 
 
Even though B-cell functions are crucial during inflammation, these cells were reported in reduced 
frequencies during TB disease (Joosten et al., 2016). B-cells are activated through engagement of 
their B-Cell Receptor (BCR) with soluble or membrane-bound antigens. Activated B-cells have 
increased expression of surface immunoglobulin CD38 (Damle et al., 2007). This activation further 
leads to differentiation and expansion within  B-cell population which is indicated by increased 
expression of surface IL-5Rα (Katoh et al., 1993). During M.tb inflammatory responses, B-cells 
mediate several functions which involve various B-cell differentiation such as plasma cells, killer and 
regulatory B-cells. Regulatory characteristics in B-cells is associated with increased IL-10 secretion 
which is inducible at any stage during B-cell development (Iwata et al., 2011). However, 
characterization of their exact phenotype and function during TB disease is still a growing field. 
Regulatory B-cells have been previously defined at varying frequencies within CD5+, CD5+CD1d+ 
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and CD24+CD27+CD38+ B-cell populations (van Rensburg et al., 2017; van Rensburg and Loxton, 
2018; Yanaba et al., 2008; Zhang et al., 2012). These cells mediate two main functions which involve 
maintaining invariant Natural killer cells (iNK) homeostasis and immunosuppression. They suppress 
immune responses by affecting T-cell differentiation, mainly T-helper type 1 (Th1) and 17 (Th17) 
cells through suppression of pro-inflammatory cytokines produced by antigen presenting cells (APC) 
(Zhang et al., 2012). Apart from secreting IL-10 as a major anti-inflammatory cytokine, B-regs can 
also suppress immune responses through IL-35 and TGF-β cytokines which regulate immune 
responses by stimulating apoptotic pathways in CD4+ and CD8+ T-cell (Rosser et al., 2015). 
Additionally, expression of Fas-L and PD-L1 on these cells enhance their immune regulatory function 
through induction of apoptotic pathways in metabolically exhausted cells flagged with receptors for 
these ligands. Regulatory traits in B-cells can be induced by various antigens including Toll-Like 
Receptor-9 agonist (TLR-9a), bacterial Lipopolysaccharide (LPS), and Bacille-Calmette Guerin 
(BCG). However, mechanisms involved in this are largely unknown and needs to be further studied 
(du Plessis et al., 2016a; van Rensburg and Loxton, 2018). A study by Tang et al., (2016)  using 
mouse models showed that extracellular BiP can upregulate expression of Fas-L, IL-10 and PD-L1 
by isolated B-cells in vitro. 
 
Expression of these cytokines and surface markers is modulated by metabolic pathways and 
transcription factors within the cell. These pathways are modulated with respect to the extracellular 
environment and calcium homeostasis as main factors which are highly important for cell activation, 
survival and differentiation. During B-cell activation through the binding of B-cell Receptor (BCR) 
to antigenic material, phosphoinositol-3-kinase (PI3K) becomes phosphorylated and activated which 
further mediate the Akt/mTOR pathway (Fruman and Limon, 2012). It has been shown that B-cell 
proliferation and functionality highly depend on this pathway and this has been reported to be greatly 
enhanced by a Th2-cell cytokine IL-4 (Fruman and Limon, 2012; Okkenhaug and Vanhaesebroeck, 
2003). Akt/mTOR pathway plays a central role in calcium homeostasis, activation of protein kinase 
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C and translocation of necrosis factor kappa beta (NFκβ) transcription factors, all of which are vitally 
important for cellular function. Formation of auto-phagosomes has been shown to depend on mTOR 
modulation among others, which include inositol signalling pathway, calcium/ calpain signalling and 
cyclic adenoside monophosphate (cMAP) (Jung et al., 2010).  mTOR Activation inhibits autophagy 
formation whereas its blockage enhances the formation of auto-phagosomes (Ravikumar et al., 2004). 
These conditions are also known to upregulate ER stress sensors which are involved in unfolded 
protein response (UPR). The ER stress response pathway, UPR, is regarded as a survival mechanism 
that cells use during high demand of immunoglobulin. This pathway promotes cell survival through 
various mechanisms which include the destruction of synthesized proteins, transcription and 
translation termination (Gass et al., 2002). However, it has also been shown that prolonged ER stress 
responses promote autophagy and activation of apoptotic pathways within the cell (Rashid et al., 
2015). This response is mainly mediated by BiP, an ER chaperone protein that can act as an 
autoantigen when released to extracellular fluids (Bläss et al., 2001) and cause functional changes on 
immune cells during chronic inflammation such as arthritis rheumatoid, cancer and allograft. 
 
Research gap and study rationale 
Challenges associated with M.tb infection control are reported worldwide. Infected immune cells are 
known to undergo necrotic cell death thus promoting further spread of the pathogen within its host; 
this highlights the need to establish new strategies directed at host immune responses that can lead to 
better infection control and shortened treatment time. This may be achieved through manipulation of 
the host immune system which may involve suppression of adaptive immune responses and induction 
of apoptotic pathways in infected cells. A B-cell subset expressing an anti-inflammatory cytokine 
(IL-10) that suppresses pro-inflammatory responses mediated by T-cells during TB infection was 
demonstrated to be inducible (du Plessis et al., 2016). Furthermore, expression of apoptosis-inducing 
ligand (Fas-L) and receptor (PD-1) was defined by van Rensburg et al., (2017) on B-cells during TB 
treatment and subsequently shown to be inducible by BCG  during latent TB infection (van Rensburg 
Stellenbosch University  https://scholar.sun.ac.za
6 
 
and Loxton, 2018). However, these B-cell characteristics were shown to be depleted during active 
TB disease characterized by prolonged inflammatory responses to M.tb. This highlighted the need to 
further explore development and functions mediated by these B-cell subpopulations during M.tb 
infection. Currently, there is limited data addressing induction and functional responses mediated by 
these cells during TB disease. Therefore, this study will increase our understanding of B-regs 
frequencies in the Peripheral Blood Mononuclear Cells (PBMC) from both healthy and latently 
infected participants and how these cells respond to extracellular BiP during active TB disease. 
 
Hypothesis 
BiP can induce anti-inflammatory response with increased expression of killer (regulatory) phenotype 
on B-cells during M.tb exposure.  
Aim 
To evaluate the effect of binding immunoglobulin protein (BiP) on induction of anti-inflammatory 
responses, killer (regulatory) B-cells and modulation of Akt/ mTOR during M.tb exposure. 
 
Objectives 
Overall objective 
To characterize the effect of BiP on the peripheral blood mononuclear cells during exposure to M.tb. 
Specific Objectives 
Our aim was achieved through the following:  
❖ Assess extracellular BiP secretion in plasma samples over the course of anti-TB treatment. 
❖ Determine cytokine secretion from unstimulated and antigen (including BiP) stimulated cells 
using multiplex assays. 
❖ Determine phenotypic changes in B-cells and T-cells by flow cytometry following antigenic 
stimulation with BiP. 
❖ Assess intracellular pathway activation through targeting Akt/mTOR signalling. 
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Study groups description 
Completion of this study involved participant groups at different TB stages regardless of human 
immunodeficiency virus (HIV) status; all participants were above 18 years and gave informed 
consent: 
❖ Healthy participant/ control (CTRL) group; with negative QuantiFERON status and no 
previous traces of M.tb infection. 
❖ Latently infected group; recently diagnosed QuantiFERON positive participants. 
❖ Active TB at diagnosis (TBdx); characterised by positive QuantiFERON status, positive 
sputum cultures and positive lung x-ray profiles. 
❖ Anti-TB treatment group at week 1 (W1) 
❖ Anti-TB treatment group at month 2 (M2) 
❖ Anti-TB treatment group at month 6 (M6) 
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Chapter 2 
Effect of Binding Immunoglobulin Protein (BiP) on 
inducing regulatory B-cells during inflammation and 
disease 
 
 
 
 
The work presented here has been formatted in the style of Biomarkers in Medicine 
journal to which it currently submitted and under review. 
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Summary 
Immune responses result from different immune cells acting in a synergistic manner to successfully 
fight infections. Nonetheless, these require a high degree of regulation to prevent excessive 
production of inflammatory products leading to other disease forms. This was previously defined as 
mediated by T-cells; however, growing studies indicate the involvement of B-cells in this regard. 
These are specialized types of B-cells that express and secrete specific regulatory markers (FasL, PD-
L1 and GITR) and soluble substances (Granzyme-B, sFasL, TGF-β, IL10 and IL35). These subsets 
are classified based on surface immunoglobulin expression and their frequencies range from 0.1-12% 
of the total B-cell population. Their functionality has been reported to resolve inflammation during 
autoimmune diseases (such as rheumatoid arthritis and collagen-induced arthritis) and cancer. 
Chronic infection such as TB affect their frequencies, however, they have been shown to be inducible 
in a murine experiment using binding immunoglobulin protein (BiP). Here we define regulatory B-
cell immunity and effects posed by BiP on the development of these cells and other immune cells. 
Cell stress associated with Mycobacterium tuberculosis (M.tb) infection lead to accumulation of 
unfolded proteins which subsequently activate BiP and 3 signal transducers (activating transcription 
factor 6 (ATF6), protein kinase-like ER kinase (PERK) and inositol-requiring enzyme-1 (IRE-1)). 
However, BiP can be translocated from endoplasmic reticulum (ER) to the extracellular environment 
where binds to immune cells and lead to functional changes. 
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Immunity, B-cells and regulatory B-cell responses during inflammation (autoimmune/ 
infection) 
Immunological studies have shown that successful clearance of any invading pathogen depends on 
the effective balance between immune cells and their secreted products such as cytokines, antibodies, 
and chemokines. Depending on the nature of infection, immune cell balance can be altered through 
biological processes such as necrosis, pyroptosis, programmed cell death and apoptosis (Brennan and 
Cookson, 2000).  These cellular processes are triggered mostly by intracellular pathogens such as 
M.tb which has evolved mechanisms of suppressing immune responses by effector T-cells through 
the release of bacterial vesicles that expresses lipoarabinomannan (LAM) and other lipoglycans 
(Athman et al., 2017). These bacteria suppress immune activation through recruitment of 
mesenchymal stem cells (MSC) which secretes immunosuppressive cytokine and nitric oxide (NO) 
(Raghuvanshi et al., 2010). Even though Bacillus Calmette-Guerin (BCG) vaccination has been in 
use for years as it stimulates immune system and shortens specific antibody response against M.tb 
infection, which targets  LAM embedded on their cell wall (de L. Costello et al., 1992), there is still 
a need for advances that will better eradicate or control the infection. These antibodies are secreted 
by a subpopulation of B-cells (plasma cells) furthermore they facilitate rapid cell mediated immunity 
through pathogen opsonization and binding of their Fc gamma receptors (FcγR) with professional 
antigen presenting cells (pAPC) which result in internalization of the pathogen (de Valliere et al., 
2005). However, M.tb is known to reside and multiply within these APC leading to the formation of 
granuloma structures (Davis et al., 2002; Davis and Ramakrishnan, 2009). Dissemination of these 
granulomatous structures and progression to active tuberculosis has been shown to affect the 
frequency of immunological cells such as circulating peripheral B-cells (Joosten et al., 2016; Ma et 
al., 2014). Tuberculosis (TB) pathogen takes advantage of this imbalance in the immune system and 
multiplies further, thus infecting more and more cells. Immune system inadequacy or manipulation 
by M.tb highlighted the importance of exploring other functions played by immune cell subtypes as 
a means to better control infection. It has become evident through research studies that regulatory 
Stellenbosch University  https://scholar.sun.ac.za
19 
 
functions in different immunological cells, including B-cells, plays more than just a role of 
suppressing aggressive immune responses during autoimmune and infectious diseases.  These 
regulatory subsets play a major role in balancing the immune system and facilitate better elimination 
and control of pathogens and resolving inflammation (Bernard A et al., 2018; Guo et al., 2015; Holan 
et al., 2014; Ray et al., 2012). Immune suppression functions are mediated by a group of specialized 
regulatory cells in the innate (myeloid derived suppressor cells (MDSCs) and Natural Killer (NK) 
cells) (Cooper et al., 2001; Serafini et al., 2008) and adaptive arms, mainly of the T (regulatory T 
cells (T-regs) and B-lymphocytes (regulatory B-lymphocytes (B-regs)) (Guo et al., 2015; Mahic et 
al., 2006) which expresses differential surface receptors and secretes varying range of cytokine 
profiles. Development of regulatory B-cells and other B-cells subtypes with different immune 
function (Figure 2.1)  is enhanced by various factors including activated/ stimulated cellular pathway, 
type of stimulant and extracellular concentration of micronutrients (Holan et al., 2014). In particular, 
regulatory function in B-cells was first described in Experimental Autoimmune Encephalomyelitis 
(EAE) (Wolf et al., 1996). It was initially thought that the primary function of these B-regs was to 
maintain the immune environment until regulatory T-cells are matured enough to take over the role. 
As depicted in Figure 2.1 and Figure 2.2, these cells exert their effect through secretion of soluble 
proteins (blocking specific intracellular pathway) and expression of surface ligand molecules such as 
Fas-L, FoxP3 and Programmed Death (PD) ligand (Guo et al., 2015; Khan et al., 2015) which enhance 
interaction with cells bearing receptors for those specific ligands and induce apoptosis or programmed 
death.  
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Figure 2.1: Different B-cell functional response to inflammation. Stimulation of any of the B-cell 
function depends on the nature of pathogenic material, whereas memory B-cells are long lasting 
immunological memory cells which bear specific receptors from the previous infection. 
 
Regulatory B-cells have been implicated in many inflammatory studies including allograft tolerance, 
cancer,  autoimmune diseases and infection (K. M. Lee et al., 2014; Li et al., 2016; Ma et al., 2014) 
where they have been shown to inhibit function and proliferation of T helper 1 and T helper 17 cells 
(Carter et al., 2011; Flores-Borja et al., 2013; Zhang et al., 2012). During autoimmune diseases, these 
cells increase tolerance of self-antigens and thus preventing the destruction of the body’s own cells. 
Similarly, during infection inflammatory responses they limit the aggressiveness of the immune 
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system and prevent persisting immune responses after clearance of the pathogen. Even though B-regs 
have not been extensively studied during TB disease, current evidence suggests that B-cells with anti-
inflammatory properties are present in smaller numbers in the peripheral stream and these decrease 
drastically during chronic infectious diseases (du Plessis et al., 2016a; van Rensburg et al., 2017a; 
Zhang et al., 2012). These cells are displayed at higher frequencies in healthy individuals and 
disappear over time during chronic immune responses thus leading to immune system imbalance 
(Joosten et al., 2016; Li et al., 2016; van Rensburg et al., 2017a). Regulatory B-cells are continuously 
reported to be dysfunctional during inflammation; furthermore, this is thought to be associated with 
exacerbation of disease state, especially in autoimmune diseases (Fillatreau et al., 2002).  
Various antigens are known to drive the development of regulatory B-cells through upregulation of 
IL-10 secretion and these include BiP, BCG, lipopolysaccharide (LPS), infectious agents and Toll-
like receptor 9 agonist (TLR-9a) (du Plessis et al., 2016b; LENERT et al., 2005; Tang et al., 2016). 
In particular, BiP has been shown to resolve inflammation in rheumatoid arthritis by upregulating 
anti-inflammatory cytokine production by immune cells (Corrigall et al., 2009; Yoshida et al., 2011).  
However, as depicted in Figure 2.2 biological pathways involved in the development of these cells 
by different antigens including BiP remains unknown. 
 
Figure 2.2: Biological pathways involved in the development of regulatory B-cells by various 
extracellular antigens have not yet been characterized and need further investigations. 
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Additionally, functional and phenotype characterization of these cells is still expanding in the context 
of different inflammatory conditions and new makers are still being identified which relates to 
extracellular environment composition during their development. It has been shown by recent studies 
that apart from IL-10 secretion, these cells are capable of secreting other soluble molecules including 
sFas-L, TGF-b, granzyme-B and IL-35 which plays crucial roles in suppressing inflammation (Guo 
et al., 2015; Tang et al., 2016; Zhang et al., 2016). 
 
Phenotypic identified subsets of regulatory B-cells during inflammation. 
Identification of regulatory B-cells is based on both extracellular surface immunoglobulin expression 
and cytokine profile, merely because these properties determine the mode of regulation by these cell 
types.  As postulated in figure 2.3 there are four common categories of B-regs and these include IL-
10 producing B-regs (commonly known as B10 cells) which produce IL-10 as major cytokine 
(Yanaba et al., 2009), Transforming Growth Factor-β producing B-cells (B-TGF-β) and FoxP3 
expressing B-cells (B-FoxP3) (Guo et al., 2015). Additionally, IL-35 is another cytokine secreted by 
regulatory B-cells, either alone or in conjunction with IL-10, to modulate immune responses during 
inflammation (Shen et al., 2014). Several phenotypes have been identified based on extracellular 
surface immunoglobulin expression within each B-regs category in various studies of both humans 
and murine. In humans, the majority of IL-10 expressing regulatory B-cells are represented by the 
expression of CD19+CD24hiCD38hi, CD1dhiCD5+, CD19+TIM1+ on their surface (Ma et al., 2014; 
Matsushita et al., 2008; Yanaba et al., 2009; Zhang et al., 2012). Similarly, Shen et al., (2014) also 
described a sub-population of IL-35 producing regulatory B-cells differentiating from plasma cells 
expressing the phenotype IgM+CD138hiTACI+CRCX+CD1d+Tim1int in murine (Shen et al., 2014). 
However, IL-21 has been shown to drive regulatory function in B-cells by upregulating expression 
of Granzyme-B in conjunction with IL-10. This subset has been phenotypically identified as 
CD19+CD38+CD147+CD1d+IgM+ (Lindner et al., 2013). Contradicting results in relation to IL-10 
were observed during a human immunodeficiency virus (HIV) study whereby GraB+ B-regs did not 
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produce IL-10 (Kaltenmeier et al., 2015; Lindner et al., 2013). B-cell regulatory function linked with  
FasL and PD-L1 expression has been described in both inflammatory and healthy state in humans; 
these appear in varying frequencies in relation to inflammatory state and they were reported to be 
higher in healthy individuals than in infected individuals (Tang et al., 2016; van Rensburg et al., 
2017a). CD19+FasL+ and CD19+PD-L1+ regulatory subsets secrete IL-10; although intracellular 
pathways are not fully exploited regarding IL-10 bio-synthesis by these B-cell subpopulations (van 
Rensburg et al., 2017a; van Rensburg and Loxton, 2018). However, there have been reports that 
significant amount of IL-10 by B-cells occurs through the involvement of Toll-Like Receptor (TLR) 
molecules rather than B-cell Receptor (BCR) or CD40 involvement (Liu et al., 2014). CD1dhiCD5+ 
B-cells were reported to be inducible for IL-10 secretion in significant amounts through TLR-9 using 
LPS and intracellularly mediated by MyD88/STAT3 pathway (Bénard et al., 2018; Liu et al., 2014; 
Yanaba et al., 2009). FoxP3 expressing B-cells in healthy human blood samples were first described 
in a study by Noh et al., (2010) within the CD19+CD5+ population. These cells appeared in higher 
frequencies within the CD5+ group than in the CD5- group and they also showed to have increased 
apoptotic characteristics than other B-cell groups. A subsequent study by Guo et al., (2015) examined 
and described FoxP3 expressing CD19+ B-cells to be of greater frequencies in healthy individuals 
than in patients with rheumatoid arthritis (RA). Although further studies still need to be done on 
FoxP3+ B-cells, Guo et al., (2015) also compared their frequency with TGF-β CD19+ B-cells and 
found no significant difference amongst the expression frequencies of these groups in both healthy 
and RA groups. Regulatory function and frequency of B-cells and other immune cells is affected by 
varying antigens present in their cellular environment. 
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Figure 2.3: Circulating CD19+ B-cells have the potential to develop to regulatory B-cells with 
different regulatory markers depending on their stage of development. Regulatory trait has been 
identified within B1 cells, Marginal Zone B-cells and Transitional-2 Marginal zone B-cells. 
 
Binding Immunoglobulin Protein (BiP) affects immune cell function 
BiP is a 78 kDa heat shock protein naturally occurring in the lumen of theER which aids in proper 
peptide folding (Yoo et al., 2012). Synthesis and expression of this protein have been reported to be 
upregulated during cellular stress which might be due to glucose starvation or in response to 
accumulation of unfolded proteins within the cell (Choi et al., 2010; Lee, 2005). Its activation/ 
synthesis was initially observed in a study by Munro and Pelham, (1986) where BiP was shown to be 
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expressed in high concentrations in antibody producing B-cells due to high levels of synthesized 
immunoglobulin inhabiting ER than in resting/ naive B-cells. Gass et al., (2002) exploited the 
Unfolded Protein Response (UPR) in B-lymphocytes and found it to be induced during B-cell 
transition to antibody secreting plasma cells thus suggesting a link between upregulation of this 
protein with immunoglobulin synthesis. Loss of BiP function in B-cells has been associated with an 
inability to secrete functional antibodies which may ultimately affect opsonization of invading 
pathogens (Hu et al., 2009). In particular, M.tb infection exerts stress onto immune cells through 
secretion of ESAT-6 which affects homeostasis of calcium ions and increase unfolded protein burden 
in cells due to metabolic shift. However, it has been implied that extended ER stress can lead to 
activation of apoptotic pathways in immune cells resulting in skewed immunological responses 
(Joosten et al., 2016; Li et al., 2006). As illustrated in Figure 2.4, ER stress activates and upregulate 
expression of BiP and other ER chaperones to mitigate the conditions posed onto cells (Choi et al., 
2010). These chaperone proteins bind unfolded and partially folded proteins and direct them for 
proper folding in the ribosomes (Maddalo et al., 2012). They also act as co-activators of three ER 
membrane signal transducers; PERK, IRE1 and ATF6 (Figure 2.4), which in turn phosphorylates 
transcription factors and cytosol kinase involved in translation termination and cytokine synthesis. 
These mechanisms either promote cell apoptosis or cell survival.  
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Figure 2.4: Unfolded Protein Response mediated by BiP. Activation of the ER membrane transducers 
leads to a cascade of kinases phosphorylation that either favour apoptosis through upregulation of 
CHOP and JNK activation. Similarly, cell survival can be favoured by blocking translation and 
degrading synthesized mRNA.  
 
Even though BiP is natively an intracellular protein; it has been reported to be able of translocating 
to and expressed on cell membranes attached to peripheral proteins including both transmembrane 
proteins and external proteins such as glycosylphosphotidylinositol (GPI) and similarly secreted into 
the extracellular environment (Tsai et al., 2015) where it acts as an autoantigen and exert effects on 
immune cells through binding with surface receptors (Corrigall et al., 2004; Zhang et al., 2010). Over 
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the last years, its effect has been exploited in different immune cells including macrophages, dendritic 
cells, monocytes, T-cells and B-cells. BiP facilitates differentiation of mature dendritic cells to 
express anti-inflammatory phenotype through upregulation of Indoleamine-2,3-Dioxygenase (IDO) 
(Corrigall et al., 2009) and also stimulate myeloid cells to express an anti-inflammatory phenotype 
mostly observed in immature dendritic cells (Yang et al., 2016). In a study by Corrigall et al., (2004) 
BiP was shown to act on human peripheral blood mononuclear cells (PBMCs) to induce anti-
inflammatory responses through upregulation of IL-10. It also affects the expression of CD86 and 
HLA-DR surface expression in monocytes which caused these antigen presenting cells (APCs) to be 
unable of activating T-cells. BiP effects also alter the ability of memory T-cells to recall antigens and 
initiate secondary responses. Immunological effects caused by BiP has ultimately established study 
platforms in areas relating to cancer, transplantation, and autoimmune studies (Brownlie et al., 2006; 
Yoshida et al., 2011). Contradicting results however were observed in Giardia lamblia infection in 
murine samples where recombinant BiP extracted from Giardia lamblia (rGlBiP) showed to promote 
pro-inflammatory responses through upregulation of CD80, CD86 and MHC II  on mature dendritic 
cells leading to increased production of pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α 
(H.-Y. Lee et al., 2014). Another study by (Yoo et al., 2012)) showed that cell surface BiP expression 
can be upregulated by pro-inflammatory such as TNF-α an IL-1β. Additionally, this upregulation was 
associated with increased proliferation of synoviocyte cells and progressive pathogenesis of 
rheumatoid arthritis in synoviocytes. This suggested that cell surface BiP can modulate pro-
inflammatory responses in synoviocytes. Interestingly, transfection of BiP gene into murine and 
human PBMC samples using a viral vector has been evaluated as having the same anti-inflammatory 
effects as stimulating with synthesized proteins in collagen arthritis inflammation (Shields et al., 
2015). Supporting evidence of extracellular BiP binding to immune cells was shown in a study by 
Tang et al., (2016) where BiP induced the development of regulatory B-cells in murine samples and 
worked in synergy with CD40 to suppress proliferation of T-cells. 
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Binding of extracellular BiP with immune cells 
BiP is a member of heat-shock proteins (Hsp70) that have been reported to have immune modulatory 
functions. Unlike other members of Hsp70 which are implicated in the induction of pro-inflammatory 
immune responses, BiP is reported to mostly facilitate anti-inflammatory responses. As a result, this 
chaperone has been studied in the induction of functional changes in immune cells (Bläss et al., 2001; 
Bodman-Smith et al., 2003; Corrigall et al., 2004). Secreted BiP binds to cell receptors as an 
autoantigen and causes functional changes. However, pathways involved in these processes are not 
fully elucidated (Figure 2.2), but it has been stated that most of the Hsp70 proteins are secreted 
through passive secretion. Studies on rheumatoid arthritis and cancer that have identified extracellular 
BiP observed that it is secreted without its anchor,  a four amino acid sequence KDEL thus suggesting 
that it’s not available as a result of membrane rupture or cell death (Corrigall et al., 2004). In 
particular, a study in murine collagen induced arthritis (CIA) revealed an IL-4 dependent effect of 
BiP on T cell responses which leads to secretion of anti-collagen specific cytokines including IL-5 
and IL-10 (Brownlie et al., 2006). Even though BiP upregulation is beneficial to immune responses 
as it activates signal transducers that mediate cytokine and antibody gene expression, similarly, its 
downregulation has been associated with benefits in cancer suppression which could be a target of 
choice in studies such as B-cell lymphoma. Targeting this chaperone could be a promising approach 
that will aid in the development of new therapeutic procedures that will better control inflammation 
during diseases (Corrigall et al., 2009; Yang et al., 2016). Less data has been generated on binding of 
extracellular BiP onto immune cells since previous studies focused mainly on monitoring the cytokine 
profile in immune cell samples in the presence of BiP rather than assessing binding receptors or 
pathways involved during internalization. However, it has been suggested in a study by Becker et al., 
(2002) that free Hsp70 proteins bind immune cells, such as B-cells, through CD40 in an ATPase 
dependent manner. Even though this pathway has not been fully studied but BiP binding with immune 
cells such as B-cells was also shown by Tang et al., (2016) using fluorescently labeled BiP in a murine 
model. Binding and internalization of this chaperone protein on B-cell samples induced upregulation 
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of 3 populations of regulatory B-cells with distinct phenotypes (IL-10hi, PDL-1, and FasL) and thus 
highlighting different regulatory mechanisms (Tang et al., 2016).  
 
Regulatory function of mature/active regulatory B-cells 
Initial studies on regulatory B-cells implied that these cells were only modulating immune responses 
until regulatory T-cell mature enough to take over the function. However, further studies elaborated 
on immune functions played by these cells using murine models and have repeatedly shown that 
regulatory B-cells exert their function mostly through IL-10 (Matsushita et al., 2008; Yanaba et al., 
2009). Similar results have been obtained in human models, where both cytokines and cell surface 
receptors are implicated in the regulatory roles of these cells (Blair et al., 2010). Even though their 
development depends on various factors including the type of stimulant and the presence of 
micronutrients to drive immunometabolism; these cells have been shown to inhibit proliferation and 
function of macrophages, T helper 1 (Th1) and T helper 17 (Th17) cells while leaving T helper 2 
(Th2) function unaffected (Flores-Borja et al., 2013). In various studies, this was confirmed by a 
decrease in secreted levels of cytokines such as Interferon gamma and Interleukin 17 (IL-17) while 
IL-4 levels were not affected by the presence of regulatory B-cells (Flores-Borja et al., 2013; Zhang 
et al., 2012). Regulatory B-cell importance is associated with maintaining immune balance after 
inflammatory responses in order to prevent autoimmune diseases progression by suppressing 
persisting T-cell responses (Yanaba et al., 2008). Cell-to-cell immunomodulatory function of 
regulatory B-cells occurs through the expression of ligands that target and bind to specific surface 
receptors expressed by other immune cells and this binding further enhance apoptotic pathways. Such 
immunomodulatory ligands include PDL-1 which targets PD-1 membrane protein on activated T-
cells and monocytes; Fas-L which stimulate apoptosis of infected macrophages during chronic 
infections such as TB (Oddo et al., 1998; van Rensburg et al., 2017a, 2017b); and Glucocorticoid-
Induced TNRF family-Related protein (GITR) which has been shown to be associated with negatively 
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modulating proliferation of regulatory T-cell during RA through binding to GITR-ligand expressed 
by these cells (Ray et al., 2012).  
 
Immune responses driven by low or high frequencies of regulatory B-cells 
In allograft and autoimmune diseases, high frequency of regulatory B-cells is associated with 
preventing progression into aggressive stages of inflammation. Functions carried by these cell subsets 
is highly similar to regulatory T-cells; however, these functions are believed to be alternating during 
inflammation in a sense that regulatory B-cells are mostly active during the onset of inflammation 
whereas regulatory T-cells come to action towards the end of inflammation. This notion has been 
supported in a variety of studies where regulatory B-cells were isolated in higher frequencies in 
healthy individuals but eventually depletes as inflammatory responses progress (Flores-Borja et al., 
2013; Matsushita et al., 2008). The same “depletion-reappearing” trait of these cells has been 
observed in studies focusing on different inflammatory responses using both murine and human 
models. Recently, it has been observed in human samples studying B-cell immune responses during 
M.tb infection and this was believed to play a part in disease progression as their numbers vanished 
during active TB disease but upon treatment of the disease; these regulatory B-cells reappeared to a 
frequency equivalent to healthy individuals (van Rensburg et al., 2017b). Expression of regulatory 
traits in B-cells has been described in varying frequencies depending on B-cell development stage, 
location and type of inflammation. Highlighted in table 2.1 are recently reported frequencies of 
different regulatory B-cell populations in uninfected or healthy individuals and these ranges from 
0.1% to as high as 12% of the total described B-cell population. However, in-vitro these frequency 
percentages could be stimulated to increase using different stimulants amongst of which include; LPS, 
TLR-9 agonist, and BGC (Blair et al., 2010; du Plessis et al., 2016a; van Rensburg and Loxton, 2018). 
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Table 2.1: Defined regulatory B-cell population frequencies in healthy human individuals expressing 
different surface markers and exhibiting diverse regulatory mechanisms. 
Phenotype Species Percentage 
(%) 
Mechanism 
of 
suppression 
Reference 
CD24hiCD27+ Human, PBMC 0.6 IL-10 (Iwata et al., 2011) 
CD24+CD38+ 
CD24hiCD38- 
CD24hiCD38int 
CD24hiCD38hi 
 
 
 
Human 
 
3.92 
3.71 
12.6 
 
IL-10 
 
 
(Blair et al., 2010) 
CD5+CD1d+IL10+ 
 
 
Human, PBMC 
 
 
0.24±0.05 
 
 
IL-10 
 
 
(Chen et al., 2017) 
 
CD19+IgM+CD38+ 
      Fas-L+ 
      PD1+ 
 
Human, PBMC 
 
0.1-1.6 
 
Fas-L 
 
(van Rensburg et 
al., 2017a) 
CD19+IgM-CD38+ 
      Fas-L+ 
      PD1+ 
 
Human, PBMC 
 
0.1-1.5 
 
Fas-L 
 
(van Rensburg et 
al., 2017a) 
CD19+PD-L1hi 
 
CD19+CD138+CD27+ 
Human, spleen 
 
Human, PBMC 
5.2 
 
2.99 
PD-L1 
 
IL-10 
(Khan et al., 2015) 
 
(du Plessis et al., 
2016) 
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Presence of regulatory B-cells and high secretion levels of IL-10 by these cells modulate 
differentiation of certain T-cell subsets expressing CD4+CD25- T-cells to regulatory T-cells 
expressing FoxP3 which further mediate regulatory functions during inflammation (Flores-Borja et 
al., 2013).  In-vitro work has shown that high levels of IL-10 are linked to impaired secretion and 
activity of certain pro-inflammatory cytokines such as TNF-α, IL-12, IL1-β, and IL-17; these are 
required during early inflammation to initiate and activate adaptive responses by recruiting T-cells 
and B-cells. However, in the context of M.tb infection, engagement of adaptive responses has been 
speculated to favour TB disease progression through the formation of granulomas which later 
becomes replication sites for the intracellular pathogen leading to more cells being infected within 
the structure as bacterial numbers grow and infected cells rapture through cellular necrosis and 
pyroptosis. 
Conclusion and Future perspectives 
Regulatory characteristic induction by BiP in B-cells 
Less data is currently available on the induction of human regulatory B-cells using BiP indicating 
that more work still needs to be done to understand the pathways involved in the development of 
these cell types. Previous reports have shown that BiP has anti-inflammatory properties through 
induction of regulatory cells and this has been evaluated in different inflammatory studies with 
successful results (Bodman-Smith et al., 2003; Yoshida et al., 2011). Apart from inducing immune 
regulatory functions, its activity in immunoglobulin folding results in better antibody secretion which 
in turn facilitate better control of infectious pathogens (Fritz and Weaver, 2014). Its biological nature 
gives it an additional advantage by limiting non-specific inflammatory responses which may end up 
causing immuno-pathogenesis. Availability of this molecule in extracellular circulation and its 
autoantigen properties facilitate secretion of autoantibodies against it, this also displays an additional 
advantage since immune cells will efficiently opsonize and internalize it resulting in shorter time 
required for the development of regulatory traits. Induction of these traits; IL-10, Fas-L and PD-L1; 
in B-cells using BiP in a murine model study and its implication in inducing regulatory traits in T-
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cells in human model studies have paved the way and indicated a high possibility of regulatory B-
cell induction by this antigen in human settings (Tang et al., 2016). More studies must be conducted 
in the context of M.tb infection and BiP behaviour. 
 
Regulatory B-cells as agents in therapeutic interventions 
Inflammatory responses directed to intracellular pathogens such as M.tb faces challenges on directly 
eliminating the pathogen from inside the cell. This phenomenon results as pathogens such as M.tb 
have evolved a way to suppress destruction by proteolytic enzymes inside the phagosomes, 
additionally, antibodies and cytokines secreted towards this pathogen cannot penetrate cellular 
membranes to reach it, thus resulting in established infection and disease progression. Even though 
the formation of granulomatous structures during TB helps in containing the pathogen and preventing 
early spread; the pathogen may multiply to higher numbers and progress to active disease. Immune 
cell activity within the granuloma structure and upregulation of necrotic cytokines and perforins lead 
to the destruction of infected cells by necrosis which in turn leads to the release of more pathogens to 
infect other cells. Comparatively, regulatory B-cells has been suggested to induce apoptosis of 
infected cells by affecting cellular metabolism which in turn affect homeostasis of calcium, reactive 
oxygen species and nitric oxide thus affecting the survival of the intracellular pathogen. This prevents 
the presentation of antigens and activation of effector T-cells thus limiting activation of adaptive 
immune responses. Stimulating development or maintaining the frequency of these regulatory cells 
can present more benefits in host directed immunotherapies and control of intracellular pathogens 
likes M.tb. 
Acknowledgement 
BM received a bursary from the NRF program. AGL is supported by the NRF-CSUR (Grant Number 
CSUR60502163639). AGL is supported by the Centre for Tuberculosis Research from the South 
African Medical Research Council.   
Stellenbosch University  https://scholar.sun.ac.za
34 
 
References 
Athman, J.J., Sande, O.J., Groft, S.G., Reba, S.M., Nagy, N., Wearsch, P.A., Richardson, E.T., Rojas, 
R., Boom, W.H., Shukla, S., Harding, C.V., 2017. Mycobacterium tuberculosis Membrane 
Vesicles Inhibit T Cell Activation. J. Immunol. Baltim. Md 1950 198, 2028–2037. 
https://doi.org/10.4049/jimmunol.1601199 
Bénard, A., Sakwa, I., Schierloh, P., Colom, A., Mercier, I., Tailleux, L., Jouneau, L., Boudinot, P., 
Al-Saati, T., Lang, R., Rehwinkel, J., Loxton, A.G., Kaufmann, S.H.E., Anton-Leberre, V., 
O’Garra, A., Sasiain, M.D.C., Gicquel, B., Fillatreau, S., Neyrolles, O., Hudrisier, D., 2018. 
B Cells Producing Type I IFN Modulate Macrophage Polarization in Tuberculosis. Am. J. 
Respir. Crit. Care Med. 197, 801–813. https://doi.org/10.1164/rccm.201707-1475OC 
Blair, P.A., Noreña, L.Y., Flores-Borja, F., Rawlings, D.J., Isenberg, D.A., Ehrenstein, M.R., Mauri, 
C., 2010. CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals 
but Are Functionally Impaired in Systemic Lupus Erythematosus Patients. Immunity 32, 129–
140. https://doi.org/10.1016/j.immuni.2009.11.009 
Bläss, S., Union, A., Raymackers, J., Schumann, F., Ungethüm, U., Müller-Steinbach, S., De Keyser, 
F., Engel, J.M., Burmester, G.R., 2001. The stress protein BiP is overexpressed and is a major 
B and T cell target in rheumatoid arthritis. Arthritis Rheum. 44, 761–771. 
https://doi.org/10.1002/1529-0131(200104)44:4<761::AID-ANR132>3.0.CO;2-S 
Bodman-Smith, M.D., Corrigall, V.M., Kemeny, D.M., Panayi, G.S., 2003. BiP, a putative 
autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from 
normal individuals. Rheumatol. Oxf. Engl. 42, 637–644. 
Brennan, M.A., Cookson, B.T., 2000. Salmonella induces macrophage death by caspase-1-dependent 
necrosis. Mol. Microbiol. 38, 31–40. https://doi.org/10.1046/j.1365-2958.2000.02103.x 
Brownlie, R.J., Myers, L.K., Wooley, P.H., Corrigall, V.M., Bodman-Smith, M.D., Panayi, G.S., 
Thompson, S.J., 2006. Treatment of murine collagen-induced arthritis by the stress protein 
Stellenbosch University  https://scholar.sun.ac.za
35 
 
BiP via interleukin-4–producing regulatory T cells: A novel function for an ancient protein. 
Arthritis Rheum. 54, 854–863. https://doi.org/10.1002/art.21654 
Carter, N.A., Vasconcellos, R., Rosser, E.C., Tulone, C., Munoz-Suano, A., Kamanaka, M., 
Ehrenstein, M.R., Flavell, R.A., Mauri, C., 2011. Mice Lacking Endogenous IL-10-Producing 
Regulatory B Cells Develop Exacerbated Disease and Present with an Increased Frequency 
of Th1/Th17 but a Decrease in Regulatory T Cells. J. Immunol. 186, 5569–5579. 
https://doi.org/10.4049/jimmunol.1100284 
Chen, Y., Li, C., Lu, Y., Zhuang, H., Gu, W., Liu, B., Liu, F., Sun, J., Yan, B., Weng, D., Chen, J., 
2017. IL-10-Producing CD1dhiCD5+ Regulatory B Cells May Play a Critical Role in 
Modulating Immune Homeostasis in Silicosis Patients. Front. Immunol. 8. 
https://doi.org/10.3389/fimmu.2017.00110 
Choi, H.-H., Shin, D.-M., Kang, G., Kim, K.-H., Park, J.B., Hur, G.M., Lee, H.-M., Lim, Y.-J., Park, 
J.-K., Jo, E.-K., Song, C.-H., 2010. Endoplasmic reticulum stress response is involved in 
Mycobacterium tuberculosis protein ESAT-6-mediated apoptosis. FEBS Lett. 584, 2445–
2454. https://doi.org/10.1016/j.febslet.2010.04.050 
Cooper, M.A., Fehniger, T.A., Turner, S.C., Chen, K.S., Ghaheri, B.A., Ghayur, T., Carson, W.E., 
Caligiuri, M.A., 2001. Human natural killer cells: a unique innate immunoregulatory role for 
the CD56(bright) subset. Blood 97, 3146–3151. 
Corrigall, V.M., Bodman-Smith, M.D., Brunst, M., Cornell, H., Panayi, G.S., 2004. Inhibition of 
antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells 
to express an antiinflammatory cytokine profile by the stress protein BiP: Relevance to the 
treatment of inflammatory arthritis. Arthritis Rheum. 50, 1164–1171. 
https://doi.org/10.1002/art.20134 
Corrigall, V.M., Vittecoq, O., Panayi, G.S., 2009. Binding immunoglobulin protein-treated peripheral 
blood monocyte-derived dendritic cells are refractory to maturation and induce regulatory T-
Stellenbosch University  https://scholar.sun.ac.za
36 
 
cell development. Immunology 128, 218–226. https://doi.org/10.1111/j.1365-
2567.2009.03103.x 
Davis, J.M., Clay, H., Lewis, J.L., Ghori, N., Herbomel, P., Ramakrishnan, L., 2002. Real-Time 
Visualization of Mycobacterium-Macrophage Interactions Leading to Initiation of Granuloma 
Formation in Zebrafish Embryos. Immunity 17, 693–702. https://doi.org/10.1016/S1074-
7613(02)00475-2 
Davis, J.M., Ramakrishnan, L., 2009. The Role of the Granuloma in Expansion and Dissemination 
of Early Tuberculous Infection. Cell 136, 37–49. https://doi.org/10.1016/j.cell.2008.11.014 
de L. Costello, A.M., Kumar, A., Narayan, V., Akbar, M.S., Ahmed, S., Abou-Zeid, C., Rook, 
G.A.W., Stanford, J., Moreno, C., 1992. Does antibody to mycobacterial antigens, including 
lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans. R. Soc. Trop. Med. 
Hyg. 86, 686–692. https://doi.org/10.1016/0035-9203(92)90192-F 
de Valliere, S., Abate, G., Blazevic, A., Heuertz, R.M., Hoft, D.F., 2005. Enhancement of Innate and 
Cell-Mediated Immunity by Antimycobacterial Antibodies. Infect. Immun. 73, 6711–6720. 
https://doi.org/10.1128/IAI.73.10.6711-6720.2005 
du Plessis, W.J., Keyser, A., Walzl, G., Loxton, A.G., 2016a. Phenotypic analysis of peripheral B cell 
populations during Mycobacterium tuberculosis infection and disease. J. Inflamm. 13. 
https://doi.org/10.1186/s12950-016-0133-4 
du Plessis, W.J., Kleynhans, L., du Plessis, N., Stanley, K., Malherbe, S.T., Maasdorp, E., Ronacher, 
K., Chegou, N.N., Walzl, G., Loxton, A.G., 2016b. The Functional Response of B Cells to 
Antigenic Stimulation: A Preliminary Report of Latent Tuberculosis. PLOS ONE 11, 
e0152710. https://doi.org/10.1371/journal.pone.0152710 
Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D., Anderton, S.M., 2002. B cells regulate 
autoimmunity by provision of IL-10. Nat. Immunol. 3, 944–950. 
https://doi.org/10.1038/ni833 
Stellenbosch University  https://scholar.sun.ac.za
37 
 
Flores-Borja, F., Bosma, A., Ng, D., Reddy, V., Ehrenstein, M.R., Isenberg, D.A., Mauri, C., 2013. 
CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 
Differentiation. Sci. Transl. Med. 5, 173ra23-173ra23. 
https://doi.org/10.1126/scitranslmed.3005407 
Fritz, J.M., Weaver, T.E., 2014. The BiP Cochaperone ERdj4 Is Required for B Cell Development 
and Function. PLoS ONE 9, e107473. https://doi.org/10.1371/journal.pone.0107473 
Guo, Y., Zhang, X., Qin, M., Wang, X., 2015. Changes in peripheral CD19(+)Foxp3(+) and 
CD19(+)TGFβ(+) regulatory B cell populations in rheumatoid arthritis patients with 
interstitial lung disease. J. Thorac. Dis. 7, 471–477. https://doi.org/10.3978/j.issn.2072-
1439.2015.02.11 
Holan, V., Zajicova, A., Javorkova, E., Trosan, P., Chudickova, M., Pavlikova, M., Krulova, M., 
2014. Distinct cytokines balance the development of regulatory T cells and interleukin-10-
producing regulatory B cells. Immunology 141, 577–586. https://doi.org/10.1111/imm.12219 
Hu, C.-C.A., Dougan, S.K., Winter, S.V., Paton, A.W., Paton, J.C., Ploegh, H.L., 2009. Subtilase 
cytotoxin cleaves newly synthesized BiP and blocks antibody secretion in B lymphocytes. J. 
Exp. Med. 206, 2429–2440. https://doi.org/10.1084/jem.20090782 
Iwata, Y., Matsushita, T., Horikawa, M., DiLillo, D.J., Yanaba, K., Venturi, G.M., Szabolcs, P.M., 
Bernstein, S.H., Magro, C.M., Williams, A.D., Hall, R.P., St Clair, E.W., Tedder, T.F., 2011. 
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse 
regulatory B10 cells. Blood 117, 530–541. https://doi.org/10.1182/blood-2010-07-294249 
Joosten, S.A., van Meijgaarden, K.E., del Nonno, F., Baiocchini, A., Petrone, L., Vanini, V., Smits, 
H.H., Palmieri, F., Goletti, D., Ottenhoff, T.H.M., 2016. Patients with Tuberculosis Have a 
Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful 
Treatment. PLOS Pathog. 12, e1005687. https://doi.org/10.1371/journal.ppat.1005687 
Kaltenmeier, C., Gawanbacht, A., Beyer, T., Lindner, S., Trzaska, T., van der Merwe, J.A., Härter, 
G., Grüner, B., Fabricius, D., Lotfi, R., Schwarz, K., Schütz, C., Hönig, M., Schulz, A., Kern, 
Stellenbosch University  https://scholar.sun.ac.za
38 
 
P., Bommer, M., Schrezenmeier, H., Kirchhoff, F., Jahrsdörfer, B., 2015. CD4 + T Cell–
Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of 
Granzyme B–Expressing Regulatory B Cells in HIV Patients. J. Immunol. 194, 3768–3777. 
https://doi.org/10.4049/jimmunol.1402568 
Khan, A.R., Hams, E., Floudas, A., Sparwasser, T., Weaver, C.T., Fallon, P.G., 2015. PD-L1hi B 
cells are critical regulators of humoral immunity. Nat. Commun. 6, 5997. 
https://doi.org/10.1038/ncomms6997 
Lee, A.S., 2005. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic 
reticulum stress. Methods 35, 373–381. https://doi.org/10.1016/j.ymeth.2004.10.010 
Lee, H.-Y., Kim, J., Noh, H.J., Kim, H.-P., Park, S.-J., 2014. Giardia lamblia binding 
immunoglobulin protein triggers maturation of dendritic cells via activation of TLR4-MyD88-
p38 and ERK1/2 MAPKs. Parasite Immunol. 36, 627–646. https://doi.org/10.1111/pim.12119 
Lee, K.M., Stott, R.T., Zhao, G., SooHoo, J., Xiong, W., Lian, M.M., Fitzgerald, L., Shi, S., Akrawi, 
E., Lei, J., Deng, S., Yeh, H., Markmann, J.F., Kim, J.I., 2014. TGF-β-producing regulatory 
B cells induce regulatory T cells and promote transplantation tolerance: Immunomodulation. 
Eur. J. Immunol. 44, 1728–1736. https://doi.org/10.1002/eji.201344062 
LENERT, P., BRUMMEL, R., Field, E.H., ASHMAN, R.F., 2005. TLR-9 Activation of Marginal 
Zone B Cells in Lupus Mice Regulates Immunity Through Increased IL-10 Production. J. 
Clin. Immunol. 25, 29–40. https://doi.org/10.1007/s10875-005-0355-6 
Li, J., Lee, B., Lee, A.S., 2006. Endoplasmic Reticulum Stress-induced Apoptosis MULTIPLE 
PATHWAYS AND ACTIVATION OF p53-UP-REGULATED MODULATOR OF 
APOPTOSIS (PUMA) AND NOXA BY p53. J. Biol. Chem. 281, 7260–7270. 
https://doi.org/10.1074/jbc.M509868200 
Li, W., Tian, X., Lu, X., Peng, Q., Shu, X., Yang, H., Li, Y., Wang, Y., Zhang, X., Liu, Q., Wang, 
G., 2016. Significant decrease in peripheral regulatory B cells is an immunopathogenic feature 
of dermatomyositis. Sci. Rep. 6. https://doi.org/10.1038/srep27479 
Stellenbosch University  https://scholar.sun.ac.za
39 
 
Lindner, S., Dahlke, K., Sontheimer, K., Hagn, M., Kaltenmeier, C., Barth, T.F.E., Beyer, T., Reister, 
F., Fabricius, D., Lotfi, R., Lunov, O., Nienhaus, G.U., Simmet, T., Kreienberg, R., Moller, 
P., Schrezenmeier, H., Jahrsdorfer, B., 2013. Interleukin 21-Induced Granzyme B-Expressing 
B Cells Infiltrate Tumors and Regulate T Cells. Cancer Res. 73, 2468–2479. 
https://doi.org/10.1158/0008-5472.CAN-12-3450 
Liu, B.-S., Cao, Y., Huizinga, T.W., Hafler, D.A., Toes, R.E.M., 2014. TLR-mediated STAT3 and 
ERK activation controls IL-10 secretion by human B cells. Eur. J. Immunol. 44, 2121–2129. 
https://doi.org/10.1002/eji.201344341 
Ma, L., Liu, B., Jiang, Z., Jiang, Y., 2014. Reduced numbers of regulatory B cells are negatively 
correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin. 
Rheumatol. 33, 187–195. https://doi.org/10.1007/s10067-013-2359-3 
Maddalo, D., Neeb, A., Jehle, K., Schmitz, K., Muhle-Goll, C., Shatkina, L., Walther, T.V., 
Bruchmann, A., Gopal, S.M., Wenzel, W., Ulrich, A.S., Cato, A.C.B., 2012. A peptidic 
unconjugated GRP78/BiP ligand modulates the unfolded protein response and induces 
prostate cancer cell death. PloS One 7, e45690. https://doi.org/10.1371/journal.pone.0045690 
Mahic, M., Yaqub, S., Johansson, C.C., Taskén, K., Aandahl, E.M., 2006. FOXP3+CD4+CD25+ 
Adaptive Regulatory T Cells Express Cyclooxygenase-2 and Suppress Effector T Cells by a 
Prostaglandin E2-Dependent Mechanism. J. Immunol. 177, 246–254. 
https://doi.org/10.4049/jimmunol.177.1.246 
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M., Tedder, T.F., 2008. Regulatory B cells 
inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 
https://doi.org/10.1172/JCI36030 
Oddo, M., Renno, T., Attinger, A., Bakker, T., MacDonald, H.R., Meylan, P.R., 1998. Fas ligand-
induced apoptosis of infected human macrophages reduces the viability of intracellular 
Mycobacterium tuberculosis. J. Immunol. Baltim. Md 1950 160, 5448–5454. 
Stellenbosch University  https://scholar.sun.ac.za
40 
 
Raghuvanshi, S., Sharma, P., Singh, S., Van Kaer, L., Das, G., 2010. Mycobacterium tuberculosis 
evades host immunity by recruiting mesenchymal stem cells. Proc. Natl. Acad. Sci. 107, 
21653–21658. https://doi.org/10.1073/pnas.1007967107 
Ray, A., Basu, S., Williams, C.B., Salzman, N.H., Dittel, B.N., 2012. A Novel IL-10-Independent 
Regulatory Role for B Cells in Suppressing Autoimmunity by Maintenance of Regulatory T 
Cells via GITR Ligand. J. Immunol. 188, 3188–3198. 
https://doi.org/10.4049/jimmunol.1103354 
Serafini, P., Mgebroff, S., Noonan, K., Borrello, I., 2008. Myeloid-Derived Suppressor Cells Promote 
Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells. Cancer Res. 68, 
5439–5449. https://doi.org/10.1158/0008-5472.CAN-07-6621 
Shen, P., Roch, T., Lampropoulou, V., O’Connor, R.A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, 
V.D., Jaimes, Y., Daridon, C., Li, R., Jouneau, L., Boudinot, P., Wilantri, S., Sakwa, I., 
Miyazaki, Y., Leech, M.D., McPherson, R.C., Wirtz, S., Neurath, M., Hoehlig, K., Meinl, E., 
Grützkau, A., Grün, J.R., Horn, K., Kühl, A.A., Dörner, T., Bar-Or, A., Kaufmann, S.H.E., 
Anderton, S.M., Fillatreau, S., 2014. IL-35-producing B cells are critical regulators of 
immunity during autoimmune and infectious diseases. Nature 507, 366–370. 
https://doi.org/10.1038/nature12979 
Shields, A.M., Klavinskis, L.S., Antoniou, M., Wooley, P.H., Collins, H.L., Panayi, G.S., Thompson, 
S.J., Corrigall, V.M., 2015. Systemic gene transfer of binding immunoglobulin protein (BiP) 
prevents disease progression in murine collagen-induced arthritis: Lentiviral delivered BiP 
reduces inflammation. Clin. Exp. Immunol. 179, 210–219. https://doi.org/10.1111/cei.12456 
Tang, Y., Jiang, Q., Ou, Y., Zhang, F., Qing, K., Sun, Y., Lu, W., Zhu, H., Gong, F., Lei, P., Shen, 
G., 2016. BIP induces mice CD19(hi) regulatory B cells producing IL-10 and highly 
expressing PD-L1, FasL. Mol. Immunol. 69, 44–51. 
https://doi.org/10.1016/j.molimm.2015.10.017 
Stellenbosch University  https://scholar.sun.ac.za
41 
 
Tsai, Y.-L., Zhang, Y., Tseng, C.-C., Stanciauskas, R., Pinaud, F., Lee, A.S., 2015. Characterization 
and Mechanism of Stress-induced Translocation of 78-Kilodalton Glucose-regulated Protein 
(GRP78) to the Cell Surface. J. Biol. Chem. 290, 8049–8064. 
https://doi.org/10.1074/jbc.M114.618736 
van Rensburg, I.C., Kleynhans, L., Keyser, A., Walzl, G., Loxton, A.G., 2017a. B-cells with a FasL 
expressing regulatory phenotype are induced following successful anti-tuberculosis treatment: 
TB treatment induces FasL regulatory B cells. Immun. Inflamm. Dis. 5, 57–67. 
https://doi.org/10.1002/iid3.140 
van Rensburg, I.C., Loxton, A.G., 2018. Killer (FASL regulatory) B cells are present during latent 
TB and are induced by BCG stimulation in participants with and without latent tuberculosis. 
Tuberculosis 108, 114–117. https://doi.org/10.1016/j.tube.2017.11.010 
van Rensburg, I.C., Wagman, C., Stanley, K., Beltran, C., Ronacher, K., Walzl, G., Loxton, A.G., 
2017b. Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA. 
Oncotarget 8, 2037–2043. https://doi.org/10.18632/oncotarget.12184 
Wolf, S.D., Dittel, B.N., Hardardottir, F., Janeway, C.A., 1996. Experimental autoimmune 
encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184, 2271–
2278. 
Yanaba, K., Bouaziz, J.-D., Haas, K.M., Poe, J.C., Fujimoto, M., Tedder, T.F., 2008. A Regulatory 
B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent 
Inflammatory Responses. Immunity 28, 639–650. 
https://doi.org/10.1016/j.immuni.2008.03.017 
Yanaba, K., Bouaziz, J.-D., Matsushita, T., Tsubata, T., Tedder, T.F., 2009. The Development and 
Function of Regulatory B Cells Expressing IL-10 (B10 Cells) Requires Antigen Receptor 
Diversity and TLR Signals. J. Immunol. 182, 7459–7472. 
https://doi.org/10.4049/jimmunol.0900270 
Stellenbosch University  https://scholar.sun.ac.za
42 
 
Yang, M., Zhang, F., Qin, K., Wu, M., Li, H., Zhu, H., Ning, Q., Lei, P., Shen, G., 2016. Glucose-
Regulated Protein 78-Induced Myeloid Antigen-Presenting Cells Maintained Tolerogenic 
Signature upon LPS Stimulation. Front. Immunol. 7. 
https://doi.org/10.3389/fimmu.2016.00552 
Yoo, S.-A., You, S., Yoon, H.-J., Kim, D.-H., Kim, H.-S., Lee, K., Ahn, J.H., Hwang, D., Lee, A.S., 
Kim, K.-J., Park, Y.-J., Cho, C.-S., Kim, W.-U., 2012. A novel pathogenic role of the ER 
chaperone GRP78/BiP in rheumatoid arthritis. J. Exp. Med. 209, 871–886. 
https://doi.org/10.1084/jem.20111783 
Yoshida, K., Ochiai, A., Matsuno, H., Panayi, G.S., Corrigall, V.M., 2011. Binding immunoglobulin 
protein resolves rheumatoid synovitis: a xenogeneic study using rheumatoid arthritis synovial 
membrane transplants in SCID mice. Arthritis Res. Ther. 13, R149. 
https://doi.org/10.1186/ar3463 
Zhang, M., Zheng, X., Zhang, J., Zhu, Y., Zhu, X., Liu, H., Zeng, M., Graner, M.W., Zhou, B., Chen, 
X., 2012. CD19+CD1d+CD5+ B cell frequencies are increased in patients with tuberculosis 
and suppress Th17 responses. Cell. Immunol. 274, 89–97. 
https://doi.org/10.1016/j.cellimm.2012.01.007 
Zhang, Y., Liu, R., Ni, M., Gill, P., Lee, A.S., 2010. Cell Surface Relocalization of the Endoplasmic 
Reticulum Chaperone and Unfolded Protein Response Regulator GRP78/BiP. J. Biol. Chem. 
285, 15065–15075. https://doi.org/10.1074/jbc.M109.087445 
Zhang, Y., Morgan, R., Chen, C., Cai, Y., Clark, E., Khan, W.N., Shin, S.-U., Cho, H.-M., Al Bayati, 
A., Pimentel, A., Rosenblatt, J.D., 2016. Mammary-tumor-educated B cells acquire 
LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses. Int. Immunol. 
28, 423–433. https://doi.org/10.1093/intimm/dxw007 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
43 
 
Chapter 3 
The level of the endoplasmic reticulum stress chaperone 
protein - Binding Immunoglobulin Protein (BiP) 
decreases following successful TB treatment. 
 
 
 
The work presented here has been formatted in the style of the International Journal 
of Infectious Disease to which it has been accepted for publication. 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
44 
 
The level of the endoplasmic reticulum stress chaperone protein - 
Binding Immunoglobulin Protein (BiP) decreases following successful 
TB treatment. 
Bongani Motaung, Gerhard Walzl and Andre G Loxton 
 
DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical 
Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human 
Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South 
Africa, PO Box 241 Cape Town, 8000 South Africa 
 
 
Keywords: TB treatment, M.tb, Binding Immunoglobulin Protein, Endoplasmic Reticulum stress 
 
Word count: 3697 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
45 
 
Abstract 
Increased Mycobacterium tuberculosis (M.tb) burden inside the host leads to higher demand of 
response proteins. This in turn results in metabolic shift and cellular stress which is caused by the 
accumulation and trafficking of these proteins within the endoplasmic reticulum (ER). To resolve 
this, cells trigger Unfolded Protein Response (UPR) which is mainly mediated by Binding 
Immunoglobulin Protein (BiP)/ Glucose Regulated Protein 78 (GRP78) chaperone, which in turn 
upregulates its transcription. This chaperone protein facilitates proper protein folding within the ER, 
however, it can also be passively secreted to the extracellular environment or be expressed on cell 
surfaces attached to anchor proteins and transmembrane proteins. This notion has been shown in 
chronic inflammatory studies including cancer and arthritis detecting BiP specific antibodies from 
different sample types. This study analysed secreted BiP from plasma samples collected from healthy 
participants, newly diagnosed TB (TBdx) cases and over the course of TB treatment at week 1 (W1), 
month 2 (M2) and month 6 (M6). Our results revealed that during initial TB disease and treatment 
period, cells are subjected to stress conditions resulting in metabolic shifts which lead to secretion of 
intracellular UPR mediating chaperone protein, BiP. This was indicated by mean differences between 
TBdx (mean 40.88 ng/ml) and W1 (68.57 ng/ml) in TB participant groups. However, no difference 
was observed between the healthy group (mean 42.64 ng/ml) and TBdx (mean 40.88). Analyzing 
paired time point visits revealed increased BiP secretion during early TB treatment. Detection of BiP 
from plasma samples showed to decrease after successful TB treatment period to levels comparable 
to healthy control in our study groups. Evaluation of BiP levels in larger TB treatment studies may 
lead to the identification of a new target for early TB diagnosis and host directed immunotherapy. 
Introduction 
Binding Immunoglobulin Protein (BiP), also referred to as Glucose Regulated Protein 78 (GRP78), 
is an endoplasmic reticulum (ER) chaperone protein that plays a crucial role during protein synthesis 
by mediating proper protein folding through binding with polypeptide structures entering the ER 
lumen (Maddalo et al., 2012; Morris et al., 1997). Even though BiP interact with peptides, however, 
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its function is not required for extracellular secretion of proteins. This chaperone protein resides in 
the ER lumen, in an inactive state attached to three membrane transducer proteins (Inositol Requiring 
Enzyme-1 (IRE1), Protein kinase R-like Endoplasmic Reticulum kinase (PERK) and Activating 
Transcription factor-6 (ATF-6)). Activation of this chaperone occurs during conditions that pose 
cellular stress (Gass et al., 2002), specifically on ER, triggering Unfolded Protein Response (UPR) 
which has been reported as a cell survival mechanism. During this, a series of events may occur which 
may include termination of transcription and translation, destruction of unfolded or misfolded 
proteins through ubiquitination, and upregulation of GRP78/BiP expression (Rao and Bredesen, 
2004). Even though this response is chiefly mediated by BiP/GRP78, it also requires the activity of 
the three signal transducers localized in ER membrane (IRE1, PERK and ATF-6) which 
phosphorylates cytosol kinases, and these metabolic pathways determine cell fate during UPR by 
either promoting cell survival or apoptosis. During UPR, BiP/GRP78 transcription is upregulated and 
this is mediated by the transcription factor YY1 which binds at the promoter region of the BiP gene. 
This transcription factor also acts as a cofactor for activation of ATF6 which is reported to be very 
essential during initiation of ER stress response (Baumeister et al., 2005). BiP upregulation has also 
been shown to be influenced by the activity of some pro-inflammatory cytokines, particularly TNF-
α and IL-1β (Yoo et al., 2012). Research studies have also shown that during chronic inflammation 
and prolonged ER stress, BiP can translocate other cell compartments such as cell membrane where 
it can be attached to transmembrane proteins or glycosylphophatidylinositol (GPI) proteins. A study 
by Tsai et al., (2015) suggested that BiP can also escape ER lumen to other cell compartments 
attached to recently synthesized proteins. This could imply that during UPR, BiP may be secreted to 
the extracellular fluids through these similar process as it was shown that its substrate binding activity 
was more important in this regard (Tsai et al., 2015). Previous studies have reported on cell-free BiP 
in association with disease exacerbation, however, these focused on chronic diseases such as cancer 
and autoimmune disease (Bläss et al., 2001; Bodman-Smith et al., 2003; Zhang et al., 2010). 
However, mechanisms involved in secretion of this chaperone to extracellular fluids are not clearly 
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defined and it is also thought to escape during membrane repair by ER vesicles (Zhang et al., 2010). 
In an extracellular phase, this chaperone has been shown to act as an autoantigen on immune cells 
and leads to metabolic shifts which affect cell function (Bodman-Smith et al., 2003). Presence of BiP 
in extracellular fluids has been shown in different sample types including serum, plasma, and synovial 
fluid. Varying disease outcomes have been associated with extracellular BiP which shows to be both 
beneficial and detrimental. This chaperone protein was reported to be overexpressed in rheumatoid 
arthritis (RA) through detection of autoantibodies secreted specifically against it. During RA 
extracellular BiP was reported to upregulate anti-inflammatory responses which have been previously 
reported to be beneficial in resolving inflammation (Corrigall et al., 2004). Contradictory results were 
also reported where extracellular BiP was shown to enhance the progression of RA in synoviocyte by 
promoting proliferation of synoviocytes which in turn enhanced angiogenesis (Yoo et al., 2012). 
Additionally, the presence of this chaperone protein in the extracellular phase was reported to promote 
prognosis of RA by affecting the activity of cytotoxic T-cells (Bläss et al., 2001). Similarly, BiP 
pathogenesis has been reported during cancer inflammation and it is suggested that downregulation 
of BiP synthesis and activity can be beneficial in resolving cancer conditions by restricting synthesis 
of vital proteins required by the cancer cells (Schwarze and Rangnekar, 2010). Immunological 
response modifications associated with this chaperone protein led to research interests to evaluate its 
secretion during the anti-TB treatment period in infected participants. Previous immunological 
response studies highlighted dysfunctionality within B-cell subset in response to TB and this may be 
in part brought into play by the extracellular matrix. Extracellular BiP binding may lead to 
intracellular metabolic shifts that affect the expression of both soluble proteins and expression of cell 
surface proteins.  
Method and Materials 
 Ethics statement 
Ethical approval was obtained from the ethics committee of the Stellenbosch University Health 
Research Ethics Committee (N05/11/187) and the City of Cape Town City Health. The study was 
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conducted according to the Helsinki Declaration and International Conference of Harmonization 
guidelines. Written informed consent was obtained from all study participants. 
Sample description  
Blood samples were collected from participants recruited in the Sarepta area of Cape Town in the 
Western Cape region of South Africa. This included both male and female participants aged between 
18-64 years old. Plasma samples were collected from a total of 81 participants; these included 42 
male participants and 39 female participants. Collected samples were categorized into 2 major groups; 
healthy controls (32 participants) which had no indication of M.tb infection based on sputum culture, 
X-ray and Quantiferon release assay; and active TB disease group at diagnosis (TBDx) (29 
participants) who had a  positive sputum culture, X-ray with signs and symptoms suggestive of TB 
disease. TB cases were placed on treatment and followed up for three time points; week-1 (W1), 
month-2 (M2) and month-6 (M6). Collected plasma samples were then stored at -80oC till analysis. 
Enzyme Linked ImmunoSorbent Assay (ELISA) analysis 
Collected plasma samples were recovered from the biorepository and analysed through ELISA. These 
samples included 32 healthy controls. TB disease group plasma samples included 29 baseline TB 
(diagnosis) with follow up time point visit of 8 participants in week-1, 7 participants in month-2, and 
19 participants in month-6 follow-up visit, in addition, 20 new participants were recruited during M6 
time point. Plasma samples were completely thawed at room temperature before ELISA analysis. 
These were then centrifuged at 1000 xg for 5 minutes to pellet any particulate material which might 
interfere with analyte binding. The Human GRP78 (Glucose Regulated Protein 78) ELISA kit from 
MyBioSource (MBS2533401, San Diego, USA), with a minimum sensitivity of 0.375 ng/ml and a 
detection range of 0.625-40 ng/ml was used as per manufacturer’s instructions. The kit is specified to 
have no cross reactivity or interference between analogues and human GRP78. ELISA plates were 
read using the Bio-Rad iMark Microplate reader (California, USA) at a recommended wavelength of 
450 nm. 
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Statistical Analysis 
Obtained optical density (OD) readings were analysed using GraphPad PRISM 7 for Windows, 
GraphPad Software, (La Jolla, California USA, www.graphpad.com).  BiP concentrations were 
analysed for differential expression between groups using the One-Way non-Parametric ANOVA, 
Mann Whitney t-test and unpaired t-test. 
Results  
 BiP levels remain unchanged at diagnosis of active TB compared to healthy controls 
In Figure 3.2 it is evident that even though BiP is an ER resident chaperone protein it can be secreted 
into plasma in small quantities even in healthy individuals. BiP secretion between participant groups 
showed a statistically significant difference (p=0.0270) with healthy group (mean 42.64 ng/ml) and 
TB diagnosis (mean 40.88 ng/ml) having comparable mean expression. BiP secretion was 
upregulated during early TB treatment (week 1) which showed the highest mean of 68.57 ng/ml. 
Furthermore, detection of BiP from these groups gradually decreased over the course of TB treatment 
approaching a healthy and TBdx baseline (Figure 3.2). In the second month of TB treatment (M2), 
BiP detection showed to decrease (mean= 60.92 ng/ml) and this showed further decrease by month 6 
(M6) as indicated by mean of 37.42 ng/ml. In contrast, no statistically significant difference was 
observed between healthy, TB diagnosis, month 2 and Month 6. 
 TB treatment on follow up participants between TBdx and W1 
BiP upregulation was further illustrated in TB treatment follow-up participant pairs (Figure 3.3 and 
Table 3.1) which indicate direct upregulation of this chaperone from respective individuals with 
detection range between 30.60 ng/ml–65.57 ng/ml (TBdx) and 60.18 ng/ml–86.77 ng/ml during week 
1 (W1) anti-TB treatment. This showed a significant difference (p = 0.0078) in BiP secretion between 
these two time point visits. 
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 BiP levels remain unchanged from week 1 of TB treatment till the end of therapy 
 Participant follow-up visits at month 2 anti-TB treatment showed no significant change in 
extracellular BiP detection (Figure 3.4) with their respective diagnosis time point with p= 0.1563 and 
a detection range between 58.41 ng/ml – 64.80 ng/ml as shown in Table 3.1. BiP detection at the end 
of anti-TB treatment (month 6) indicated a detection range between 56.64 ng/ml and 73.45 ng/ml; 
this showed no significant difference with BiP detection during TBdx (p = 0.4800) (Table 1). 
Discussion 
In this study, we have provided evidence that during TB disease treatment, Unfolded Protein 
Response (UPR) is activated leading to upregulation of intracellular mediators such as BiP which in 
turn escapes to extracellular phase. Activation of UPR is regarded as a survival mechanism which 
cells utilize to cope with a high demand for response proteins during inflammation (Lin et al., 2007). 
Mycobacterium tuberculosis infection is classified into different infections stages with latently 
infected individuals (LTBI) at the early stage of infection where the bacterium is thought to be 
contained (Flynn and Chan, 2001). During this time, immune cells are subjected to minimal metabolic 
shift resulting in minimal stress response activation; this is evident in our results by non-significant 
different in BiP secretion levels between healthy participants and those diagnosed as positive for M.tb 
infection through sputum cultures, interferon gamma release assay (IGRA) and X-ray results. This 
finding compares with what has been shown in other studies done in cancer and arthritis showing that 
during prolonged stress conditions, cells activate UPR response resulting in secretion of intracellular 
ER chaperone proteins amongst which include BiP (Bodman-Smith et al., 2003; Zhang et al., 2005). 
Even though mechanisms involved in this are not fully elucidated, it has been suggested that cells 
elude these intracellular components through passive mechanisms during ER vesicle translocation or 
they can also be released in conjunction with their protein substrates (Tsai et al., 2015). M.tb has been 
shown to be able to manipulate and avoid innate immune responses and multiply within the host 
(Raghuvanshi et al., 2010; Sia et al., 2015), this leads to the increased bacterial burden which may 
eventually activate UPR due to the high demand of immunoglobulin and metabolic shift. This leads 
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to secretion of these mediators to the extracellular phase where they affect disease outcome. However, 
pharmacological agents have also been implicated in activating UPR (Srinivasan et al., 2005). This 
may suggest that TB treatment regimens also participate in upregulation of UPR as they need to be 
metabolized by cells, mainly liver cells, into inactive form before being eliminated from the body. 
This results in metabolic shifts within the cells which forces them to upregulate transcription and 
synthesis of specific protein compounds to mitigate the condition, these including BiP. The latter 
phenomenon can be correlated with the high secretion levels (Figure 3.2) of this stress response 
protein during the initial treatment period which is also characterized by a sharp decline in bacterial 
numbers. Even though BiP is upregulated during initial metabolic shifts (Bodman-Smith et al., 2004); 
transcription and protein synthesis become stabilized with unchanged conditions or decline with 
resolved inflammation. Theoretically, during TB treatment period, the decrease in bacterial burden 
over time should result in decreased metabolic demand from activated immune cells and this 
correlated with our findings where extracellular BiP showed to stabilize and gradually decrease after 
week 1 into TB treatment. Similarly, the switch of TB drugs after month 2 (from 4 drugs to two) and 
decreased bacterial burden does not facilitate further upregulation of UPR also because apart from 
other TB regimen rifampicin is not metabolized in the body suggesting even laser protein demand. 
Even though activation of UPR is considered a cell survival mechanism, it has also been shown that 
prolonged response triggers cell death through apoptotic pathways by upregulation of the 
transcription factor C/EBP homologous protein (CHOP) (Mozos et al., 2011). The latter can be 
beneficial for infection control since TB disease is caused by an intracellular pathogen and inducing 
apoptosis results in cell death from within by limiting metabolites flux which are vital for M.tb 
survival. Apoptotic pathways are known to prevent early cell membrane rapture thus limiting the 
spread of M.tb to uninfected cells. This is opposite to necrotic pathways which have been implicated 
to be utilized by the pathogen in question to infect and reside in other immune cells. Upregulation of 
BiP in the cellular microenvironment has been shown to induce the anti-inflammatory response in 
immune cells either by upregulation of IL-10 synthesis (Yoshida et al., 2011) or upregulation of 
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surface markers involved in programmed cell death (Tang et al., 2016). Our study, evaluating the 
utility of secreted BiP over the course of TB treatment must be seen as an initial assessment as the 
number of participants with active TB were relatively low. Even though BiP levels were detected 
with a standard methods, however, protein degradation might have occurred over time resulting in 
lower levels of this respective biomarker. Future studies must evaluate BiP levels from a larger group 
of freshly isolated plasma and serum samples from participants at different M.tb infection stages. 
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Figures  
 
Figure 3.1: Plasma sample collection at specific time points. N= total number, TB=tuberculosis, 
TBdx= TB diagnosis, W1= week-1, M2= month-2 and M6= month-6 
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Figure 3.2: Detection of secreted Binding Immunoglobulin Protein (BiP) during TB treatment and 
healthy states. Statistical difference analysis through nonparametric one-way ANOVA, p= 0.0270; 
where CTRL=healthy group, TBdx=TB treatment group at diagnosis, W1=week 1 treatment group, 
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M2=month 2 treatment group and M6=month 6 treatment group; error bars show mean with standard 
deviation 
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Figure 3.3: Increased levels of BiP following one week of TB treatment. Sample pairs analysed for 
changes in BiP secretion one week after the start of TB treatment. Statistical difference assessed 
through nonparametric paired t-test (Wilcoxon matched pairs test) p = 0.0078, where ** = p<0.01 
 
Figure 3.4: Paired time point visits during TB treatment revealed increased secretion of BiP by TB 
treatment groups. Statistical difference assessed through nonparametric paired Friedman test, p = 
0.0057. 
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Tables 
Table 3.1: TB treatment follow-up participants; TBdx = TB diagnosis, W1= week 1 of TB treatment, 
M2 = month 2 of TB treatment, M6 = month 6 of TB treatment, N= number of participants, LB = 
lower bound and UP = upper bound. 
Variable Treatment 
Groups 
N Mean 
Levels 
(ng/ml)  
Standard 
deviation 
p-value 
 
95% CI for the 
mean 
LB          UB           
Min 
(ng/ml) 
Max 
(ng/m
l) 
BiP TBdx 
W1 
 
TDdx 
M2 
 
TBdx 
M6 
8 
8 
 
7 
7 
 
19 
19 
52 
67.91 
 
50.06 
60.92 
 
59.50 
64.59 
14.95 
8.78 
 
15.03 
2.10 
 
12.90 
4.43 
0.0078 
 
 
0.1563 
 
 
0.4800 
 
36.5 
60.57 
 
36.16 
58.98 
 
52.87 
62.31 
64.5 
75.25 
 
63.96 
62.86 
 
66.13 
66.87 
30.60 
60.18 
 
30.60 
58.41 
 
30.60 
56.64 
65.57 
86.77 
 
62.74 
64.80 
 
79.36 
73.45 
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Abstract 
Mycobacterium tuberculosis (M.tb) infection remains a threat with a high mortality rate worldwide 
despite the availability of anti-tuberculosis (TB) treatment. This highlight the importance of 
establishing new measures to mitigate the infection. Host directed therapies (HDT) represent a 
promising platform through the discovery of novel host biomarkers and induction of immune cell 
subpopulations that will aid in better control of TB disease. Regulatory B-cells are continuously 
implicated in resolving chronic inflammation and has been isolated and shown to regulate responses 
through various mechanisms including secretion of anti-inflammatory cytokines and expression of 
cell surface ligands such as IL-10, IL-35, TGF-β, granzyme-B, Fas-L, PD-L1 and FoxP3. Previous 
studies have shown that these B-cell characteristics can be induced by different antigenic material 
during bacterial and viral infections. Here, we explored the ability of Binding Immunoglobulin 
Protein (BiP) to induce a regulatory B-cell phenotype in vitro, from mycobacterium tuberculosis 
(M.tb) exposed and unexposed healthy participants. We evaluated cell surface expression and 
secreted cytokine profile from 8 stimulation conditions, including unstimulated and stimulated with 
antigens: human recombinant BiP full-length protein (20ug/ml), H37Rv (MOI: 1:10), TLR-9a (0.5 
µM), INH (1 µM), BiP plus TLR-9a, pooled BAL at TB Diagnosis (TBdx) and month 6 (M6) TB 
treatment. We found that BiP upregulated the co-expression of Fas-L (CD178) and IL5Rα (CD125) 
in both healthy (p=0.0147) and M.tb infected participants (LTBI) (0.0216). This chaperone showed 
synergy with TLR-9a to further upregulate the co-expression in both healthy (0.0002) and LTBI 
(p=0.0015). However, the cytokine profile in BiP stimulated samples showed a significant decrease 
in Interleukin (IL)-10 (QFN positive p=0.0350); conversely, increased soluble Fas-L (sFasL) 
(p=0.0402), IL-4 (QFN negative p=0.0006; QFN positive p=0.0043), IL-5 (QFN positive p=0.0002) 
and IL-13 (QFN negative p=<0.0001; QFN positive p=0.0006). H37Rv resulted in elevated levels of 
IL-1β (p=0.0001) in quantiferon positive group, Tumor Necrosis Factor-alpha (TNF-α) (QFN 
negative p=0.0334; QFN positive p=0.0114) and IL-10 (QFN negative p=0.0385; QFN positive 
p=0.0004). Intracellular pathways showed increased activation of p70S6K upon exposure to H37Rv. 
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In addition, the QFN positive group had increased activation of IRS1 (0.0179) and p70S6K compared 
to the QFN negative group. Our study highlights the effects of BiP on cell functionality which in 
future could be harnessed as host directed therapy against TB disease. 
 
Introduction 
Mycobacterium tuberculosis (M.tb) infection is listed among the deadly diseases worldwide. The 
World Health Organisation estimated about 10.4 million cases of TB disease in 2016 and even with 
a 3% drop in the global TB rate each year (WHO, 2017), there is still a need to advance early detection 
of this disease and therapeutic measures. Although TB treatment is readily available, host directed 
immunotherapies (HDT) are becoming a promising adjunct platform for better control of TB disease 
(Hawn et al., 2013; Tobin, 2015). This involves targeting different aspects of the host immune system 
including immune response mediating cells and their secreted biomarkers (Tobin, 2015). In vitro 
studies have indicated that immune cells respond differently to varying antigens and that this can 
elicit either pro-inflammatory or anti-inflammatory responses (du Plessis et al., 2016; van Rensburg 
and Loxton, 2018). A subpopulation of B-cells with regulatory/killer phenotype (B-regs) was studied 
by van Rensburg et al., (2017) during the TB treatment period. However, their function during this 
chronic disease is unknown as they become dysfunctional over the course of TB treatment and re-
establish their frequencies after the successful treatment phase. Interleukin (IL)-10 secretion is 
regarded as the hallmark of regulatory B-cell (Horikawa et al., 2013), however, studies have shown 
that the regulatory functions of B-cells can equally be mediated through the expression of other 
cytokines such as IL-35 (Shen et al., 2014), Transforming growth factor beta (TGF-β) (Guo et al., 
2015; Lee et al., 2014) and to a lesser extent, expression of FoxP3 (Guo et al., 2015; Noh et al., 2010). 
This B-cell subpopulation is suggested to develop at any stage during B-cell development, even 
though the mechanisms involved have not been fully characterized (Rosser and Mauri, 2015). 
Development of regulatory phenotypes in B-cells have been shown to be induced by varying factors 
including engagement of Toll-Like Receptor (TLR) molecules (TLR 2, 4, 9), viral and bacterial 
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infection, ER stress chaperones, LPS and soluble egg antigens (SEA’s) (LENERT et al., 2005; Neves 
et al., 2010; Wang et al., 2017). During tuberculosis disease, the presence of regulatory B-cells 
showed to alter the function of Th17 cells while leaving T-helper 1 (Th1) cells unaffected suggesting 
a skewed balance between these two pro-inflammatory mediators (Torrado and Cooper, 2010; Zhang 
et al., 2012). As a result, recent studies have taken interest to the non-humoral functions of B-cells 
during inflammation and evidence suggest a growing platform of a killer/regulatory B-cells studies 
during different chronic inflammatory responses (Mauri and Menon, 2015). Killer (Fas-L+) and 
regulatory phenotype (IL-10) of B-cells was shown to be inducible in vitro by various antigens 
including BCG (van Rensburg and Loxton, 2018), LPS (Yanaba et al., 2008) and TLR-9a (du Plessis 
et al., 2016) in the context of tuberculosis and other chronic diseases. These regulatory functions are 
observed within the CD5+ B-cells and CD24+CD38+ B-cells during (van Rensburg and Loxton, 2018; 
Zhang et al., 2012, 2014). In a recent study by Tang et al., (2016) an endoplasmic reticulum (ER) 
chaperone protein, Binding Immunoglobulin Protein (BiP), was shown to induce elevated levels of 
IL10 in isolated murine B-cells with upregulated expression of death inducing ligands; Fas-L and 
PD-L1. BiP is an ER chaperone protein residing in the lumen in an inactive form attached to three 
membrane transducers. This chaperone protein has been shown to escape the ER through various 
mechanisms including passive translocation with recently folded proteins and translocation with cell 
membrane proteins (Tsai et al., 2015). Its upregulation has been reported to be induced by stress 
conditions and pro-inflammatory cytokines such as IL-1β and TNF-α (Yoo et al., 2012) When 
exposed or secreted to the extracellular space it act as an autoantigen which bind and drive immune 
cell responses mainly towards anti-inflammatory responses (Bodman-Smith et al., 2003; Corrigall et 
al., 2009, 2004; Tang et al., 2016; Yoshida et al., 2011). In this study, we aim to evaluate the ability 
of BiP to drive anti-inflammatory responses and induce a regulatory/ killer phenotype in B-cells 
during exposure/infection with M.tb. 
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Material and Methods 
Ethics statement 
Ethical approval was obtained from the Stellenbosch University Health Research Ethics Committee 
(N16/05/070). All participants gave written informed consent before participating in the study. 
Participant description 
A total of 20 participants were recruited for this study who were all HIV negative. As illustrated in 
Table 4.1, these included 12 healthy participants with no traces of previous exposure to M.tb (QFN 
negative) and 8 latent TB infected (LTBI) individuals (QFN positive) as indicated by the Interferon 
Gamma Release Assay (IGRA) and chest X-ray. Study participant’s age ranged between 24 and 58 
years old with a Mean ± SD of 32.1 ± 9.2. 
 
Table 4.1: Participant clinical and demographic information 
Participant Groups Gender N Mean age ± SD 
Male Female 
Total (N) Participants 
QFN Negative 
8 
4 
12 
8 
20 
12 
32.1 ± 9.2. 
29.5 ± 6.0 
QFN Positive 4 4 8 36.0 ± 12.1 
QFN= QuantiFeron, N= participant number, SD= standard deviation 
 
Peripheral blood mononuclear (PBMC) isolation and processing 
Sodium heparin tubes were drawn for PBMC isolation, using a Ficoll Paque (GE Healthcare Life 
Sciences) gradient method. Isolated PBMCs were cryopreserved in 10% dimethylsulfoxide (DMSO) 
and stored at -80oC in a Mr Frosty overnight after which it was transferred to liquid nitrogen (LN) 
until further experimental work. 
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PBMC overnight stimulation 
Cells were thawed and the viability by trypan blue exclusion method ranged between 93% and 100%. 
Approximately 1 x 106 cells/well were dispensed into a 96 well culture plate for each stimulation 
condition. Samples were stimulated in a Biosafety level-3 facility under the following conditions: 
unstimulated PBMC, BiP (20 µg/ml, SPR 119A, StressMarq Biosciences inc, Canada), Toll-like 
Receptor-9 agonist (TLR-9a) (0.5 µM, Miltenyi Biotech, USA), Mycobacterium tuberculosis Strain 
H37Rv (MOI 1:10), Isoniazid (INH) (1 µM, Sigma-Aldrich cat:55-85-3, South Africa), BiP+TLR-9a 
(respective concentrations), pooled broncho-alveolar lavage (BAL) fluid from untreated TB at 
diagnosis (TBdx) and pooled BAL at month 6 (M6) of TB treatment. Culture plates were incubated 
at 37oC (5% CO2) for 24 hours after which culture supernatants were collected and stored at -80
oC. 
The cell pellet was fixed, cryopreserved and stored in LN till further analysis.  
Multi-cytokine and kinase analysis 
Luminex multiplex assay (magnetic bead based) was used for measuring cytokine secretion in culture 
supernatants. These included: IL-1β, IL-4, IL-5, IL-10, IL-13, TNF-α, granzyme B, Fas-L (R&D 
systems cat: LXSAHM-08, USA) TGF-β1, TGF-β2 and TGF-β3 (Merck cat: TGFBMAG-64K-03, 
USA). Plates were analysed using the MAGpix (Bio-Rad, USA) and Bioplex200 (Bio-Rad, USA) 
instruments.  
a) Kinase activity multiplex 
Stimulated cells were recovered from LN and split into two for all stimulation conditions with ~0.5 
x 106 cells used for kinase activity and the remaining cells used for flow cytometry analysis. 
Intracellular kinases were measured for respective stimulation conditions and these included: Akt, 
mTOR, GSK3α, IGF1R, IR, IRS1, p70S6K, PTEN, RPS6 and TSC2 (Merck cat: 48-612MAG, USA). 
Stimulated PBMC were lysed with provided lysis buffer in the presence of a freshly prepared protease 
inhibitor cocktail (Merck cat: 535140-1SET, USA). The lysates were filtered through 0.65 µm low 
protein binding Durapore PVDF filters (Merck cat: UFC40DV25, USA) and analysed. 
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Flow cytometric analysis of B- and T-cell lymphocytes 
Commercially available monoclonal antibodies were used to measure cell surface expression of CD3-
PerCP, CD5-APC-CY7, CD19-BV510, CD38-PE-CY7, CD125-PE, CD178-APC, CD279-BV421, 
IgM-FITC (all antibodies supplied by BD). Figure 4.1 and 4.2 shows the gating strategy to identify 
killer B-cells and death receptors on T-cells. Fluorescence-Minus-One (FMO) controls were used to 
determine gating cut-off. 
   
 
Figure 4.1: Gating strategy to determine killer B-cells isolated from human PBMC. Activated killer 
B cells were identified as CD19+CD5+ CD38+IgM+ B-cells co-expressing CD178 (Fas-L) and CD125 
(IL-5Rα).  The expression of CD279 (PD-1) was measured within the IgM+CD38+ B-cell population. 
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Figure 4.2: Gating strategy followed to assess phenotypic changes within CD3+CD5(lo) and 
CD3+CD5(hi) activated T-cells on expression of FasL, PD-1 and IL-5Rα.                        
Data analysis 
Statistical analysis was performed in Statistica 13 (TIBCO Software inc, USA) using Variance 
Estimation and Precession (VEPAC) to test for significant differences in cytokine secretion. Flow 
cytometry analysis was done using Flowjo software version 10 (Treestar) (Flowjo lcc, USA) and 
statistical difference between cell population frequencies evaluated using GraphPad prism 8 software 
(GraphPad, USA), using multiple t-test for differences between groups and two-way ANOVA for 
differences between stimulation conditions within each group. Kinase activity results were analysed 
using GraphPad prism 8 software (GraphPad, USA), using a two-way ANOVA. 
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Results 
Expression of killer phenotype in CD19+CD5+ B-cell population 
Comparison of surface maker expression between Quantiferon (QFN) negative and positive groups 
was achieved through multiple t-test. QFN positive group showed elevated frequencies of 
CD19+CD5+ B-cell population compared to QFN negative group (presented in Figure 4.3); significant 
difference was obtained between unstimulated PBMC’s (p=0.0069) and PBMCs stimulated with 
TLR-9a (p=0.0049), H37Rv (p=0.0042), INH (p=0.0026), BAL TBdx (p=0.0014) and M6 
(p=0.0064). Furthermore, this frequency was significantly decreased by BiP plus TLR-9a stimulation 
within both participant groups (QFN negative p=0.0030 and QFN positive p=0.0151) compared to 
their respective unstimulated PBMCs. Activation of mature CD19+CD5+ B-cells as indicated by 
expression of CD38+IgM+ indicated significant upregulation by TBdx stimulation within both 
participant groups (QFN negative p=0.0001 and QFN positive p=0.0098). IL-5Ra (CD125) 
expressing cells within CD19+CD5+CD38+IgM+ were down regulated by BiP (p=0.0173) and BiP 
plus TLR-9a (p=0.0051) within QFN negative group. In contrast, this population was upregulated by 
TLR-9a stimulation in QFN positive group (p=0.0071). Additionally, IL-5Rα expression was also 
increased by H37Rv (QFN negative p=0.0111 and QFN positive p=0.0157) and TB dx (QFN negative 
p=0.0044 and QFN positive p=0.0067) stimulations within both participant groups compared to their 
respective unstimulated samples. Co-expression of Fas-L (CD178) within 
CD19+CD5+CD38+IgM+IL5Ra+ B-cell population was significantly upregulated by BiP (p=0.0216), 
BiP plus TLR-9a (p=0.0015) and TBdx (p=0.0051) within QFN positive group and similarly within 
QFN negative group (BIP p=0.0147, BiP plus TLR-9a p=0.0002 and TBdx p=0.0014) compared to 
their respective unstimulated samples. PD-1 (CD279+) expression within CD19+CD5+CD38+IgM+ 
cell population was significantly upregulated by TLR-9a (p=0.0372) in QFN-negative group and 
H37Rv (p=0.0327) in QFN positive group compared to the unstimulated samples. 
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Figure 4.3: Cell surface immunoglobulin expression within CD5+ B-cells, where B-cell 
subpopulation frequencies are represented as a) CD19+CD5+, b) CD19+CD5+CD38+IgM+, c) 
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CD19+CD5+CD38+IgM+CD125+, d) CD19+CD5+CD38+IgM+CD125+CD178+, e) 
CD19+CD5+CD38+IgM+CD178+, f) CD19+CD5+CD38+ IgM+CD279+. Statistical significance was 
tested using non-parametric multiple t-test for differences between participant groups, respective to 
stimulation conditions, and non-parametric Two-way ANOVA for differences between stimulation 
conditions within each group. Significant difference is indicated by asterisk where * = p <0.05, ** = p 
<0.01, *** = p <0.001 and **** = p <0.0001. 
Cell surface expression within CD3+CD5+ T-cells. 
a) CD5 (lo) T cell receptor expression 
Our results showed significant upregulation (Figure 4.4) of CD3+CD5lo expressing T-cells after 
stimulation with INH (p=0.0322), BiP plus TLR-9a (p=0.0178) and BAL (TBdx) (p=<0.0001) within 
QFN positive participants whereas within QFN negative this was only upregulated by BAL (TBdx) 
(p=0.0039). No significant difference was obtained in the frequency of this cell population between 
participant groups. Activation (CD38 expression) within CD3+CD5lo population was significantly 
upregulated by BAL TBdx in QFN positive group (p=0.0032). However, this activation was 
significantly downregulated by BiP plus TLR-9a within both participant groups (QFN negative 
p=0.0028 and QFN positive p=0.0032). Expression of IL-5Rα within CD3+CD5loCD38+ cell 
population was significantly upregulated by BiP stimulation (p=0.0386) in QFN negative; in addition, 
this was upregulated by BiP plus TLR-9a (QFN negative p=0.0118; QFN positive p=0.0057) and 
BAL TBdx (QFN negative p=0.0008; QFN positive p=<0.0001) within both participant groups 
compared to the unstimulated cells. Significant increase of PD-1 (CD279) expression within 
CD3+CD5loCD38+ was observed in BAL TBdx stimulation in both QFN negative (p=0.0017) and 
QFN positive (p=0.0290) groups compared to their respective unstimulated samples. Additionally, 
the expression of this receptor was significant in QFN positive compared to QFN negative group 
(p=0.0023). Fas-L single expression was not detected on these cells, however, co-expression with IL-
5Rα was detected at lower frequencies between groups and stimulation within each group (not 
significant). 
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Figure 4.4: Cell surface expression within T-cell subpopulations, where cell frequencies are 
represented as a) CD3+CD5lo, b) CD3+CD5loCD38+, c) CD3+CD5loCD38+, d) 
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CD3+CD5loCD38+CD125+CD178+, e) CD3+CD5loCD38+CD178+ and f) CD3+CD5loCD38+CD279+. 
Significant differences were tested through multiple t-test between participant groups and two-way 
ANOVA between unstimulated PBMC and other stimulation conditions within each group. 
Significant difference is indicated by asterisk where * = p <0.05, ** = p <0.01, *** = p <0.001 and **** 
= p <0.0001. 
 
b) CD5 (hi) T cells surface marker expression 
Comparison between unstimulated and stimulated PBMC within each group (Figure 4.5), showed 
upregulated frequency of CD3+CD5hi T-cells by stimulation with INH (p=0.0300), BiP plus TLR-9a 
(p=0.0214) and BAL TBdx (p=<0.0001) in QFN positive participants whereas in QFN negative this 
was only upregulated by BAL TBdx (p=0.0014). CD38 expression within CD3+CD5hi cell population 
showed significant downregulation by BiP stimulation (p=0.0315) in QFN negative; in addition, this 
was further downregulated by BiP plus TLR-9a in both QFN negative (p=0.0003) and QFN positive 
(p=0.0109). Expression of IL-5Rα within CD3+CD5hi CD38+ population was significantly 
upregulated by BiP stimulation (p=0.0130) within QFN negative groups; BiP plus TLR-9a within 
both QFN negative (p=0.0429) and QFN positive (p=0.0091) and BAL TBdx within both QFN 
negative (p=0.0003) and QFN positive (p=<0.0001). Co-expression with Fas-L was detected in lower 
frequencies within CD3+CD5hiCD38+ but upregulated by stimulation with BAL TBdx (p=0.0315) in 
QFN positive group compared to unstimulated cells. PD-1 expression was upregulated within both 
participant groups by BAL TBdx stimulation (QFN negative p=0.0014 and QFN positive p=0.0004). 
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Figure 4.5: Cell surface expression within T-cell subpopulations, where cell frequencies are 
represented as a) CD3+CD5hi, b) CD3+CD5hiCD38+, c) CD3+CD5hiCD38+, d) 
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CD3+CD5hiCD38+CD125+CD178+, e) CD3+CD5hiCD38+CD178+ and f) CD3+CD5hiCD38+CD279+. 
Significant differences were tested through multiple t-test between participant groups and two-way 
ANOVA between unstimulated PBMC and other stimulation conditions within each group. 
Significant difference is indicated by asterisk where * = p <0.05, ** = p <0.01, *** = p <0.001 and **** 
= p <0.0001. 
Cytokine profile in unstimulated and stimulated PBMCs 
PBMC stimulation with different antigens induce both anti-inflammatory and 
pro-inflammatory responses 
The heat map in Figure 4.6 shows relative secretion of cytokines from unstimulated and stimulated 
PBMCs. BiP stimulation induced strong responses of soluble Fas-L (sFas-L), IL-4, IL-5 and IL-13 
whereas IL-10 response was reduced. Combination of BiP and TLR-9a increased secretion of IL-4, 
TGF-β1 and TGF-b3 in cultured PBMCs. Stimulation with H37Rv induced the strong response of 
pro-inflammatory cytokine TNF-α with a slight increase in IL-1β, IL-4, IL-5 and IL-13. This also 
increased anti-inflammatory mediators (Granzyme-B, sFas-L and IL-10). Stimulating PBMC with 
BAL TBdx showed the strong response of pro-inflammatory (IL-1β) and anti-inflammatory (IL-13) 
cytokines with reduced IL-10 and TGF-β2 responses. In contrast, pooled BAL (M6) reduced TGF-
β2 responses, with no effect in the relative secretion of other cytokines. Furthermore, stimulating 
PBMC with TLR-9a reduced expression of pro-inflammatory TNF-α and anti-inflammatory sFas-L 
without affecting secretion of other cytokines. Further reduction in relative secretion of sFas-L and 
IL-13 is depicted during INH stimulation. 
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Figure 4.6: Heat map depicting relative secretion of cytokines from unstimulated and stimulated 
PBMCs. Stimulation condition mean values were normalised by row using feature scaling. Higher 
biomarker secretion is indicated by increased blue colour intensity. 
Cytokine secretion profiles variation between QFN negative and QFN positive 
groups. 
Comparison of 11 cytokine secretion between the two participant groups showed significant increase 
in IL-1β (p= 0.0162) secretion in QFN positive group compared to QFN negative group as shown in 
Figure 4.7. Secretion of IL-5 (p=0.0001), TGF-β2 (p=0.0135) and TGF-β3 (p<0.0001) was 
significantly upregulated by the QFN negative group. 
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Figure 4.7: Cytokine secretion profile between QFN negative and QFN positive participants a) shows 
IL-1β secretion, b) IL-5 secretion, c) TGF-β2 secretion and d) TGF-β3 secretion by stimulated 
PBMC. Significant difference is indicated by asterisk where * = p <0.05, ** = p <0.01, *** = p <0.001 
and **** = p <0.0001. 
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Varying antigens elicit different cytokine profiles in PBMC 
Figure 4.8 shows a significant difference in cytokine secretion elicited by various stimulation 
conditions within the two participant groups compared to their respective unstimulated cells. There 
was a significant upregulation of pro-inflammatory cytokine TNF-α in both QFN negative (p=0.0334) 
and positive (p=0.0114) participant groups following stimulation with H37Rv. Increased IL-1β by 
H37Rv stimulation in QFN positive (p=0.0001), additionally pooled BAL TBdx also induced 
significant upregulation of this cytokine in both QFN negative (p=0.0086) and QFN positive 
(p=0.0001) groups. Pro-inflammatory response IL-4 (QFN negative p=0.0006 and QFN positive 
p=0.0043) and IL-5 (QFN positive p=0.0002) was increased by BiP stimulation. In addition, 
stimulation with BiP plus TLR-9a further induced elevated levels of IL-4 in both participant groups 
(QFN negative p=<0.0001 and QFN positive p=0.0137). IL-13 showed high secretion following 
stimulation with BiP (QFN negative p=<0.0001 and QFN positive p=0.0006), BiP plus TLR-9a (QFN 
negative p=<0.0001 and QFN positive p=0.0022), BAL TBdx (both groups p=<0.0001) and H37Rv 
(QFN negative p=<0.0018 and QFN positive p=0.0006). Furthermore, stimulating with H37Rv 
upregulated secretion of IL-10 in both groups with a highly significant difference in QFN positive 
group (p=0.0004) compared to QFN negative (p=0.0385). Conversely, secretion of IL-10 was 
suppressed by BiP (p=0.0350), BiP plus TLR-9a (0.0120) and BAL TBdx (p=0.0179) in QFN positive 
group compared to unstimulated cells. In addition to H37Rv stimulation, Granzyme-B (p=0.0005) 
response was significantly increased in the QFN positive group. sFas-L was upregulated by BiP 
stimulation within QFN negative group (p=0.0402). Secretion of TGF-β variants showed differential 
response relative to other stimulatory antigens; TGF-β1 showed a significant increase in QFN 
negative group (p=0.0002) with BiP plus TLR-9a stimulation whereas this was not affected by other 
antigens. TGF-β2 showed significant downregulation by BAL TBdx and M6 stimulation with 
p=<0.0001 compared to unstimulated cells in both QFN positive and QFN negative groups. TGF-β3 
was significantly suppressed by both BAL TBdx (p=0.0339) and M6 (p=0.0114) stimulation in QFN 
positive group. 
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Figure 4.8: Cytokine secretion profile during PBMC stimulation in vitro with different antigens; 
measured cytokines are represented by a) TNF-α, b) sFas-L, c) IL-1β, d) IL-13, e) IL-5, f) granzyme-
B, g) IL-10, h) IL-4, i) TGF-β1, j) TGF-β2, k) TGF-β3. Error bars represent mean with standard 
deviation, significant difference is indicated asterisk where * = p <0.05, ** = p <0.01, *** = p <0.001 
and **** = p <0.0001 
  
Akt/ mTOR pathway regulation during cell stimulation with different antigens 
Fluorescent intensity (FI) values were used to analyse the regulation of activated kinases. Table 4.2 
highlights the statistical difference of activated kinases between QFN negative and positive.  
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Table 4.2: Kinase activity between QFN negative and positive groups. Differences were calculated 
by multiple t-test analysis.  
Kinases 
 
Mean of QFN 
Negative 
Mean of QFN 
positive 
Adjusted 
p-value 
GSK3b 2.8 0.6 0.5519 
IGF1R 4.0 0.4 0.5608 
IRS1 6.8 5.3 0.9810 
Akt 6.2 1.8 0.7764 
mTOR 7.3 6.7 0.9810 
p70S6K 20.5 31.1 0.4425 
IR 1.5 0.1 0.3749 
PTEN 3.1 3.6 0.9810 
GSK3a 3.1 3.0 0.9810 
TSC2 3.9 3.3 0.9810 
RPS6 3.4 0.0 0.1363 
QFN=Quantiferon,  
Figure 4.9 (a) summarises activation of kinases from QFN negative and QFN positive participant 
groups which showed no significant differences between the two groups. However, we found 
increased activation of ribosomal protein S6 kinase beta-1 (p70S6K) in both groups compared to 
other kinases. Mean Fluorescent Intensities (MFI) of phosphorylated kinases are highlighted in Figure 
4.9(b) with HepG2 Insulin control as a reference standard of detection. Results showed increased 
activity of glycogen synthase kinase-3 beta (GSK3β), Insulin-like Growth Factor-1 Receptor 
(IGF1R), Insulin Receptor Substrate- 1 (IRS1), Insulin Receptor (IR), mammalian Target of 
Rapamycin (mTOR) and Protein Kinase-B (Akt) in QFN negative group. Activity of p70S6K was 
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highly increased in both groups. Kinases such as GSK3β, IGF1R and IR were not detected in QFN 
positive group while Ribosomal Protein S6 (RPS6) activity was undetected in both participant groups. 
There was no difference in mean activity of Phosphate and Tensin Homolog (PTEN), Glycogen 
Synthase Kinase-3 alpha (GSK3α) and Tuberous Sclerosis Protein-2 (TSC2) in both groups. 
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Figure 4.9: Detection of phosphorylated kinases mediating Akt/mTOR pathway in PBMC isolated 
from QFN negative and QFN positive participants. Contingency graphs constructed using GraphPad 
prism 8 a) represents detected kinase FI between the two groups with mean and standard deviation 
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indicated by the error bars and b) represents MFI of phosphorylated kinases between the two groups 
with HepG2 insulin control as a reference standard. 
Kinase activity of p70S6K was significantly increased by H37Rv stimulation in QFN positive group 
(p=0.0192) as shown in Figure 4.10. No further differences in kinase activity between the two 
participant groups were seen, except for increased activity of IRS1 (p=0.0179) and p70S6K 
(p=0.0446) in QFN positive with BAL M6 stimulation   
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Figure 4.10: Different stimulants elicit varying proportions of phosphorylated kinases involved in 
Akt/mTOR pathway as indicated by varying fluorescent intensities. Measured kinase activity is 
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represented by a) GSK3β, b) IGF1R, c) IRS1, d) Akt, e) mTOR, f) p70S6K, g) IR, h) PTEN, i) 
GSK3α, j) TSC2 and k) RPS6. Significant difference is indicated by the asterisk where * = p <0.05. 
 
Discussion 
The growing threat posed by tuberculosis disease on the world’s population remains a challenge 
despite research advances made thus far. Progression to active TB disease is estimated at 5-10% of 
all latent TB cases (O’Garra et al., 2013). This highlights the need to further explore host mechanisms 
that may have potential in early eradication of this pathogen. This study focused on the effects of BiP 
to induce anti-inflammatory responses and upregulate expression of a killer/ regulatory phenotype on 
B-cells in comparison to other antigenic materials. Expression of death inducing ligands such as Fas-
L on B-cells is an interesting concept which has been shown to be of significance during TB disease 
and other chronic inflammations (van Rensburg et al., 2017; Wang et al., 2017). These mediate 
apoptotic pathways of infected or metabolically exhausted cells and this form of innate immune 
response has been reported to aid in better control of M.tb infection (Nguyen and Russell, 2001). 
Even though this killer phenotype on B-cells is not well described as it has been shown within 
different CD19+ subpopulation such as CD24+CD27+CD38+ and CD5+CD1d+. Here, expression of 
CD19+CD5+ on B-cells was assessed through flow cytometry; these cells remained unchanged by 
other stimulation conditions except in BiP stimulation (no statistically significant difference) and BiP 
plus TLR-9a (BiP+TLR-9a) stimulation (statistically significant difference) where their frequency 
was downregulated in both quantiferon negative and positive participant groups. This effect may be 
linked with secreted cytokine profile in these conditions, where cytokines such as IL-4, IL-5 and IL-
13 which are known to directly affect immune cell proliferation were highly expressed. In particular; 
IL-4 and IL-5 cytokines are known to drive B-cell development towards immunoglobulin secretion 
(Pène et al., 1988). Furthermore, IL-5 was shown to induce Fas-L expression on B-cells within 
CD5+CD1d+ population, however, this effect was antagonised by IL-4 in these cells (Klinker et al., 
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2013). The killer function mediated by Fas-L in B-cells is constantly associated with co-expression 
of IL5Rα which binds soluble IL-5 and mediate cell proliferation through transcription factor SOX-
4 (Geijsen et al., 2001). Even though biological functions of this killer B-cell population during TB 
disease are not clearly defined; this study shows that co-expression of Fas-L and IL5Rα is inducible 
by recombinant BiP within CD19+CD5+ B-cell population in both M.tb unexposed and latently 
infected participants. According to Tang et al., (2016)  BiP significantly upregulated expression of 
Fas-L and PD-L1 within CD19+ cells in murin, however, in the present study, upregulation of Fas-L 
showed no significant difference with unstimulated cells. This discrepancy may be attributed to 
different species types and presence of other immune cells in our stimulations whereas Tang et al., 
(2016) studied BiP effect on isolated B-cells. This antigen showed synergistic properties with TLR-
9a which binds TLR-9, a receptor that is known to be expressed by B-cells and plasmocytoid dendritic 
cells (pDC) (represent <0.2% of total PBMC) (Nair et al., 2012). In our cell stimulations, 
CD19+CD5+CD38+IgM+L-5Rα+ cell frequency showed reduced frequencies for BiP and BiP+TLR-
9a stimulations, suggesting that co-expression with Fas-L develops through upregulation of Fas-L 
within this B-cell population rather than upregulation of IL-5Rα from CD19+CD5+CD38+Fas-L+ as 
this population was not affected by most stimulation conditions. A study by Liu et al., (2018) showed 
the presence of M.tb in BAL and interestingly, our BAL fluid at TB disease diagnosis (TBdx) led to 
higher activation of CD19+CD5+ B-cells in PBMCs as indicated by CD38+ expression. Additionally, 
upregulation of both CD19+CD5+CD38+IL-5Rα+ and CD19+CD5+CD38+IL-5Rα+Fas-L+ B-cell 
populations by this stimulation indicated a changed environment mediated by M.tb infection since 
this effect was also observed with H37Rv stimulation, however, without affecting the frequency of 
CD19+CD5+CD38+IL-5Ra+Fas-L+. In contrast, BAL fluid at M6 of TB treatment had no effect on 
expression of any marker within CD19+CD5+ B-cell population. This may be linked with a sterilized 
environment in the alveolar space with less inflammatory proteins and clearance of bacterial burden.  
Balanced immune responses represent an important factor in disease elimination and prevention of 
autoimmunity. Our results are in accordance with previous studies suggesting that Mycobacterium 
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species (H37Rv) infection elicit both pro- and anti-inflammatory responses, particularly TNF-α and 
IL-10 respectively (Sahiratmadja et al., 2007). In the present study, TNF-α response was upregulated 
in both participant groups suggesting that early infection is highly mediated by this pro-inflammatory 
cytokine rather than IL-1β which were only upregulated in the quantiferon positive group. 
Upregulation of IL-1β response may be a function of memory response to M.tb antigens in this group. 
In both groups, H37Rv induced secretion of anti-inflammatory cytokines including IL-10 and IL-13 
in both unexposed and quantiferon positive participants, however, in quantiferon positive group 
compensational anti-inflammatory response due to elevated IL-1β was mediated through secretion of 
an additional anti-inflammatory mediator granzyme-B which is known to induce apoptosis (Kataoka 
et al., 1998). Secretion of these mediators during M.tb exposure may provide a suitable niche for this 
pathogen to establish latent infection due to controlled pro-inflammatory response and lower 
frequencies of cells expressing apoptosis inducing ligand (Fas-L). However, expression of PD-1 was 
significantly upregulated by H37Rv within CD19+CD5+ B-cells in quantiferon positive group. This 
receptor induces programmed cell death in metabolically exhausted cells; this effect may provide 
insight and further understanding on factors involved in B-cell dysfunctionality which was shown by 
Joosten et al., (2016) during TB disease. Additionally, the frequency of B-cell subpopulation co-
expressing Fas-L and IL-5Rα within CD19+CD38+IgM+ was also shown to be diminished during TB 
disease treatment phase (van Rensburg et al., 2017).  In this study BiP stimulation further enhanced 
immune responses mediated by T-helper-2 (Th2) cells through upregulation of IL-4 in both 
participant groups, however, IL-5 was only upregulated in quantiferon positive group. In addition to 
these pro-inflammatory responses induced by BiP, this also induced elevated levels of soluble Fas-L 
(sFas-L) in quantiferon negative groups and IL-13 in both quantiferon negative and positive group. 
sFas-L binds to Fas receptor expressed on both infected and metabolically exhausted cells to induce 
apoptotic pathways thus suppressing growth of M.tb (Oddo et al., 1998). In contrast, all TGF-β 
variants and granzyme-B secretion were not affected by BiP stimulation, however, TGF-β1 secretion 
was upregulated in a synergistic manner by BiP+TLR-9a stimulation. 
Stellenbosch University  https://scholar.sun.ac.za
96 
 
T-cell mediated immune responses are known to be induced by secreted cytokines and antigen 
peptides presented on MHC complex by other cells (Medzhitov and Janeway, 1997).  This study 
revealed differential T-cell modulation within both CD3+CD5lo and CD3+CD5hi in the presence of 
different antigens. Even though H37Rv did not result in any noticeable change within T-cell 
populations including both activation and expression of death inducing ligands, suggesting a delayed 
adaptive immune response driven by the increased IL-10 secretion (Fiorentino et al., 1991). However, 
activation of both T-cell subpopulations as indicated by CD38+ expression was effectively 
downregulated by stimulating with BiP+TLR9a in both latently infected and unexposed participants. 
Suppressing T-cell activation during M.tb infection will maintain immune responses within the innate 
arm, additionally, with increased frequencies of cell populations expressing death inducing ligand by 
these antigens leads to increased control of M.tb infection through apoptosis (Hawn et al., 2013). 
Apoptotic pathways have been suggested to better control and limit spread of this pathogens within 
its host (Oddo et al., 1998; Srinivasan et al., 2014). In our study, the addition of BAL fluid TBdx to 
PBMCs affected T-cell profile both within CD3+CD5lo and CD3+CD5hi; this reduced CD3+CD5hi 
frequency in both participant groups while significantly upregulating the frequency of CD3+CD5lo in 
QFN negative group. Previously, a study by Nambu et al., (2006) showed that elevated levels of IL-
1β facilitate T-cell activation; this notion agrees with the observed levels of IL-1β secreted by QFN 
positive participants in this stimulation condition. BAL TBdx also upregulated expression of PD-1 
and IL-5Rα on both T-cell subpopulations indicating metabolic exhaustion in these cells. Stimulating 
with TLR-9a did not affect the expression of any marker within both CD3+CD5lo and CD3+CD5hi, 
this was mainly because these cells are known to lack the receptor that binds this antigen (Nair et al., 
2012) and this was further shown by unchanged levels of T-cell cytokines IL-4 and IL-5 in this 
condition. 
In the present study, we show that intracellular pathways are differentially regulated between 
quantiferon negative and positive participant depending on the type of antigen. The upregulation of 
p70S6K in QFN positive participants by H37Rv stimulation indicates activated mTOR pathway 
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which was shown to play a role in innate immune responses in a study by Schmitz et al., (2008). 
mTOR pathway is known to modulate different cellular mechanisms such as transcription, translation, 
mitochondrial metabolisms, cell-cycle progression and autophagy (Corradetti and Guan, 2006; 
Schmitz et al., 2008). This pathway was further reported to suppress IL-1β secretion after TLR-4 
engagement, however, our results showed differential regulation of this cytokine with a high secretion 
of this cytokine by latently infected participants and unchanged secretion levels in healthy 
participants. 
Taken together these results may provide insight into the modulation of (BiP induced) intracellular 
pathways between healthy and M.tb infected participants in response to bacterial antigens. This study 
paves the way for our increased knowledge on mechanisms involved during induction of killer 
phenotype in B-cells and leads to better understanding of potential pathways to be targeted to control 
TB disease. 
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Chapter 5 
Summary and Concluding Remarks 
In the present study we hypothesised that extracellular Binding Immunoglobulin Protein (BiP) 
induces anti-inflammatory responses and induce B-cells to co-express a killer phenotype, Fas-L and 
IL-5Rα in healthy and M.tb exposed (latent TB infected) individuals. To further understand 
dysfunctionality associated with B-cells during TB disease and TB treatment, we further assessed 
secretion of this immunoregulatory protein during TB treatment and in healthy controls. Here we 
showed that immune cells are subjected to metabolic changes during early TB treatment which 
activates Unfolded Protein Response (UPR) due to high protein demand to mitigate inflammatory 
responses. This, in turn, leads to secretion of intracellular components amongst which includes BiP, 
which is also known to cause functional changes in different immune cells. Data obtained here 
indicated that progressive TB treatment resolves inflammation in TB participants leading to decreased 
UPR response as indicated by the gradual decrease of extracellular BiP concentrations towards the 
end of the treatment period. 
We further aimed to determine the effect of human recombinant BiP on the expression of Fas-L on 
human PBMCs from participants with different M.tb exposure. Isolated PBMCs were subjected to a 
broad range of antigens to assess functional responses in comparison to unstimulated cells. Results 
from this study indicated differential responses by PBMCs in both cytokine profile and cell surface 
receptor expression. It was observed that extracellular BiP can induce higher frequencies of Fas-L 
expressing B-cells within CD19+CD5+ population than our widely known antigens. In this study, we 
also learned that BiP can act in synergy with TLR-9a to increase secretion of IL-4. This synergy 
between BiP and TLR-9a further downregulate the frequency of IL-5Rα+ expressing CD19+CD5+ B-
cells in both healthy and latently infected participants while upregulating the frequency of CD3+CD5+ 
IL-5Rα+ T-cells. 
Stellenbosch University  https://scholar.sun.ac.za
106 
 
Furthermore, the cytokine profile of immune cells during exposure to different antigens was 
established. We found that H37Rv infection induces both pro- and anti-inflammatory responses, 
however, this infection highly favours secretion of IL-1β during latent TB and TNF-α in healthy 
participants. Even though BiP decreases secreted IL-10 in both healthy and latently infected 
participants, it induces anti-inflammatory responses through upregulation of soluble Fas-L (sFas-L) 
in healthy participants and induces IL-13 in both healthy and latently infected participants. 
Secreted cytokines are known to be tightly regulated by activated intracellular pathways; healthy and 
latently infected participants showed differential phosphorylation of kinases involved in both 
metabolic and transcription pathways. Stimulation with different antigens (including mycobacterial 
antigens) showed that secretion of pro- and anti-inflammatory cytokines are mediated by separate 
cellular pathways during H37Rv infection which are mediated through activation of p70S6K by 
mTOR pathway. 
Combined, these results explore B-cell phenotype expression, cytokine profile and intracellular 
pathways in response to different antigenic stimulations and showed that extracellular BiP could be 
a target of choice to increase frequencies of Fas-L, IL-5Rα and PD1 expressing cells during active 
TB disease. This strategy may have greater impact as host directed therapy by early induction of 
apoptosis in infected cells and metabolically exhausted cells. Apoptotic pathways are beneficial as 
they facilitate cell death from within the cell by limiting important metabolites thus killing the 
pathogen during the process and limiting its spread. 
 
Study Limitations 
• For the most part, our study was limited to healthy and latently infected participants – 
inclusion of participants with active TB disease would have been beneficial to understand the 
role of BiP during active disease and stress even though we set out to first understand how 
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BiP influences B-cell related immune responses (which are best studied in uncompromised 
immune systems). 
• Stimulation activity – a limited number of cells was available to activated kinases under 
different stimulation conditions. Addition of more cells could have aided to identify 
expression of kinases from both M.tb exposed and healthy participants 
• Unbiased cell surface receptor analysis – we included limited B-cell surface markers to 
investigate the regulation of Fas-L within the B-cell population and excluded other regulator 
markers such as CD24+CD38+ and the expression of CD1d within our CD19+CD5+ B-cell 
population. 
Future perspectives 
• Future studies should include additional disease groups, like active TB cases and other lung 
diseases to pinpoint TB specific responses to BiP. 
• Studies should also include additional markers of regulatory B-cells, i.e inclusion of anti-IL-
10, the proposed hallmark of a killer/regulatory B-cells induced by BiP. 
• Evaluation of the effect of BiP modulated immune responses to a multitude of M.tb strains in 
the context of antigen presentation and bacterial control. 
Conclusion 
This project highlighted the role of BiP in the induction of anti-inflammatory responses and a killer/ 
regulatory phenotype on B-cells during M.tb exposure. Our results represent a first step in establishing 
a platform for TB disease control, through limiting T-cell adaptive immune responses and possibly 
decreasing the rate of necrosis during infection. Establishing new targets directed at both intracellular 
pathway modulation and increased apoptosis factors may prove valuable as host directed therapy for 
improved M.tb infection control as these will decrease necrotic cell death and limit spread of this 
pathogen to infect more uninfected cells. 
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Appendix 
A 1: Recombinant Human GRP78 (BiP) Protein. 
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A 2: Toll-like receptor-9 agonist 
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A 3: BD anti-mouse Ig, κ negative control compensation beads 
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